Coronavirus derived polynucleotides and their use as vaccines
Replication-competent but propagation-defective SARS-CoV-2 RNA replicons with targeted deletions and miRNAs enhance vaccine safety and efficacy, inducing strong immune responses and protecting against SARS-CoV-2 infection.
Patent Information
- Application Number
- PCT/EP2024/065034
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Current vaccines against SARS-CoV-2 lack optimal safety and efficacy due to incomplete understanding of the genetic deletions' impact on replication and virulence, and existing RNA replicons are not adequately attenuated or immunogenic.
Development of replication-competent but propagation-defective SARS-CoV-2 RNA replicons with specific deletions in genes like nsp1, E, and furin cleavage sites, combined with immunomodulatory miRNAs, to create safer and more effective vaccine candidates.
The modified RNA replicons demonstrate enhanced safety and immunogenicity, inducing robust immune responses and providing protection against SARS-CoV-2 infection, with high viral titers and long-term memory effects.
Smart Images

Figure EP2024065034_05122024_PF_FP_ABST
Abstract
Description
[0001] CORONAVIRUS DERIVED POLYNUCLEOTIDES AND THEIR USE AS VACCINES
[0002] FIELD OF THE INVENTION
[0003] The present invention relates to polynucleotides comprising sequences encoding mutants of the SARS-CoV-2 RNA genome that are replication-competent and propagation-defective. The invention further relates to Virus Like Particles (VLPs), host cells and expression vectors comprising respective polynucleotides. The invention also relates to vaccine compositions comprising respective polynucleotides and their use for protecting a patient against SARS-CoV-2 infection.
[0004] TECHNICAL BACKGROUND
[0005] Coronaviruses (CoVs) are a family of single-stranded positive polarity RNA (ssRNA+) viruses that have a large RNA virus genome, ranging in length from approximately 25 to 33 kilobases (kb). During a coronavirus infection, replication of genomic RNA (gRNA) and synthesis of a set of subgenomic RNAs (sgRNAs) of positive and negative polarity occurs without retrotranscription. Coronaviruses mainly infect birds and mammals, and humans as well. The outbreak of Severe Acute Respiratory Syndrome (SARS) in 2002 and, more recently, Middle East Respiratory Syndrome (MERS) in 2012 have demonstrated the lethality of CoVs when they cross the species barrier and infect humans. In 2019, the SARS-CoV-2 outbreak in China has triggered a worldwide pandemic with much higher economic and health consequences than those caused by SARS-CoV and MERS-CoV. Vaccines against these pathogens are therefore needed and RNA replicon-based vaccines are one option.
[0006] Propagation-deficient RNA replicons are excellent platforms for vaccine generation, as they are a subtype of virus-derived vaccines, with a single infectious cycle that cannot spread from cell to cell. The deficiency in one or more essential functions (viral particle assembly and / or dissemination) makes them very safe vaccines and highly useful vectors for immunisation against infectious agents. To amplify these replicons, it is desirable to complement in trans the viral genes required for their propagation which have been previously removed. To do this, replicons can be grown in cell lines that complement and express the proteins required for their dissemination, which they lack, or by providing the missing proteins in trans using expression vectors. When replicons are grown in cells that do not complement their deficiencies, for example within the subject that has been vaccinated with that RNA replicon, they express their deficient genomes and the antigens they encode, without being able to produce infectious virions that propagate from cell to cell. The present invention relates to replication-competent but propagation-defective RNA replicons. Some of the advantages of using RNA replicons as platforms for vaccine generation are: (i) their easy intranasal administration, (ii) they have only one infection cycle due to the deleted genes, (iii) they do not integrate into the genome since they are RNAs, (iv) their biosafety; and (v) self-replication inside the cell and expression of high levels of viral antigens.
[0007] The arrangement of genes in the coronavirus genome is: 5'-UTR (untranslated region) - replicase / transcriptase - spike (S) protein - envelope (E) protein - membrane (M) protein - nucleocapsid (N) protein - 3' UTR end and poly (A) tail. All four structural proteins (S, E, M and N) contribute to the efficient formation of structurally stable viral particles.
[0008] In addition to the structural genes, the coronavirus genome contains genes encoding proteins with non-structural functions, e.g. RNA replicase / transcriptase. Other genes that do not encode structural proteins are in the genome downstream of the replicase / transcriptase gene. Some genes encoding genus-specific accessory proteins are involved in counteracting host defences. Coronavirus genes are referred to as ORF (Open Reading Frame) followed by a number. The following table describes the distribution of genes in the SARS-CoV-2 genome (Table 1) The arrangement of the genes within the viral genome is illustrated in Figure 1. The start and end nucleotides refer to the coding sequences, they do not include regulatory parts.
[0009] Table 1. Genes present and their distribution in the SARS-CoV-2 genome
[0010] ORF PROTEIN START (nt) END (nt)
[0011] 1ab pplab 266 21555
[0012] 2 S 21563 25384
[0013] 3a 3 25393 26220
[0014] 3b - 25814 25882
[0015] 4 E 26245 26472
[0016] 5 M 26523 27191
[0017] 6 6 27202 27387
[0018] 7a 7a 27394 27759
[0019] 7b 7b 27756 27887
[0020] 8 8 27894 28259
[0021] 9 N 28274 29533
[0022] 9b 9b 28305 28577
[0023] (nt) stands for nucleotide ORFs 1a and 1b encode the viral replicase, which is auto-proteolyzed leading to up to 16 non-structural proteins (nsps) encoding all functions required for viral replication (polymerase, helicase, primase, etc), RNA metabolism (exonuclease, endonuclease), viral mRNAs capping (methyltransferases) and other functions needed for the formation of membrane structures where viral replication takes place. In addition, many nsps are also involved in the modulation of the host innate immune response.
[0024] ORFs 2, 4, 5 and 9 encode the structural proteins spike (S), envelope (E), membrane (M) and nucleocapsid (N), respectively. S protein is involved in SARS-CoV-2 interaction with the host cell receptor (ACE-2) and determines viral tropism. M, E, and N proteins have an essential role in virus assembly and egress. E protein is a virulence factor. N protein interacts with the RNA viral genome to form the nucleocapsid, and this protein also has multiple functions in virus-host interaction.
[0025] It has also been described that ORFs 3ab, 6, 7ab, 8 and 9b encode accessory genusspecific proteins. Some of these proteins are involved in counteracting hosts defenses.
[0026] WO2018160977 discloses an attenuated coronavirus by an alteration in the replicase gene. The present invention is an improvement in that, by introducing changes, like the one described below on the nsp1 , numerous antigens are produced, thus increasing the efficacy of the vaccine.
[0027] The scientific article of Zhang et al., 2021, discloses a replicon competent in replication, but defective in propagation, however, the replicon of the present invention is safer due to a series of additional deletions. Additionally, the E gene is completely deleted, whereas in the replicons of the present invention the gene E is partially deleted so that it does not affect the transcription of the M gene.
[0028] The scientific article of Silvas et al. 2021 discloses the effect on pathogenicity produced by deletion of the SARS-CoV-2 ORFs individually creating attenuated viruses. This document does not disclose an RNA replicon of this virus, nor does it disclose the effect on immunogenicity of deleting these ORFs individually or combinations thereof. Additionally, it does not disclose with enough detail how the mutants were engineered. Therefore, a third party could not reproduce the viruses disclosed.
[0029] PCT / EP2022 / 083289 discloses other replication-competent and propagation-defective polynucleotides as well as the use thereof for protecting a patient against SARS-CoV-2 and other coronavirus infections. The methods disclosed in PCT / EP2022 / 083289 for cloning the SARS-CoV-2 genome and for generating mutants of the SARS-CoV-2 genome have also been used to generate the mutants of the present invention.
[0030] As illustrated by PCT / EP2022 / 083289 there is still a need for advantageous SARS-CoV- 2 polynucleotides which can be used as vaccines for inducing protection against subsequent SARS-CoV-2 infection.
[0031] SUMMARY OF THE INVENTION
[0032] For solving the problem outlined above, the present invention provides polynucleotides comprising:
[0033] (a) a polynucleotide sequence of SEQ ID NO: 42 (SARS-CoV-2A[3, E, 6 and 7] mutant) or SEQ ID NO: 43 (SARS-CoV-2A[3, E, 7 and 8] mutant); or
[0034] (b) a variant of SEQ ID NO: 42 or a variant of SEQ ID NO: 43, wherein the variant has at least 96 % identity, preferably at least 97 % or at least 98 % or at least 99 % identity to SEQ ID NO: 42 or SEQ ID NO: 43.
[0035] The present invention further provides polynucleotide as described above, wherein the variant polynucleotide sequence is further characterized in that:
[0036] (b1) the variant encodes a replication-competent mutant of the SARS-CoV-2 RNA genome, wherein replication-competent means that the mutant SARS-CoV-2 RNA genome can produce copies upon transfection of VeroE6-TMPRSS2 cells; and
[0037] (b2) the variant encodes a propagation-defective mutant of the SARS-CoV-2 RNA genome, wherein propagation-defective means that upon transfection of VeroE6- TMPRSS2 cells the mutant SARS-CoV-2 RNA genome is not able to assemble a virus or a VLP on the basis of the proteins encoded in the variant polynucleotide, which virus or VLP would be capable of infecting other VeroE6-TMPRSS2 cells.
[0038] In a related embodiment, the present invention provides polynucleotide as described above, wherein the variant polynucleotide sequence is further characterized in that:
[0039] (c) upon infection or transfection of a VeroE6-TMPRSS2 cell culture the mutant SARS-CoV-2 RNA genome is able to produce a viral titre of at least 103FFU / ml or a viral titre of at least 104FFU / ml or at least 105FFU / ml or at least 106FFU / ml.
[0040] In a preferred embodiment the polynucleotide as described above is RNA or DNA. The present invention provides Virus Like Particles (or VLPs) which comprise the polynucleotides as described above.
[0041] The invention also provides expression vectors comprising a DNA sequence comprising polynucleotides of the present invention as described above.
[0042] In a further embodiment the invention provides cells transfected with a polynucleotide according the present invention or infected with a VLP of the present invention.
[0043] The VLPs described above can be made by any method for producing respective VLPs. In one alternative the methods for producing respective VLPs comprise the steps of:
[0044] (a) transfecting a cell with an expression vector according to claim 11 , wherein the cell expresses a protein encoded by the ORF3a gene comprising SEQ ID NO: 6 or SEQ ID NO: 58 (codon-optimized 3a gene) and a polypeptide encoded by ORF E gene comprising SEQ ID NO: 7 or SEQ ID NO: 59 (codon-optimized E gene); and
[0045] (b) purifying the VLPs from the supernatant.
[0046] In a separate embodiment, the present invention provides vaccine compositions comprising a polynucleotide as described above or a VLP as described above, and optionally further comprising:
[0047] - at least one pharmaceutically acceptable excipient and / or
[0048] - at least one chemical or biological adjuvant or immunostimulant.
[0049] The vaccine compositions of the present invention can be used for protecting a patient against subsequent SARS-CoV-2 infection.
[0050] DETAILED DISCLOSURE
[0051] Definitions
[0052] The terms used to characterize the present invention are to be interpreted according to their common meaning in the art, except for the terms explicitly defined herein.
[0053] In accordance with the present invention, percent sequence identity between two polynucleotides is determined using the publicly available EMBOSS Supermatcher software using the standard settings (https: / / www.bioinformatics.nl / cgi- bin / emboss / supermatcher), which provides a combination of a word-match and Smith- Waterman local alignment algorithms.
[0054] The present invention further provides polynucleotides that are further characterized as encoding a replication-competent mutant of the SARS-CoV-2 RNA genome. The term “replication-competent” is understood as meaning that the polynucleotide can produce copies of itself upon transfection of VeroE6-TMPRSS2 cells.
[0055] The present invention further provides polynucleotides that are further characterized as encoding a propagation-defective mutant of the SARS-CoV-2 RNA genome. The term “propagation-defective” is understood as meaning that upon transfection of VeroE6- TMPRSS2 cells the polynucleotide is not able to assemble a virus or a VLP on the basis of the proteins encoded in the polynucleotide, which virus or VLP would be capable of infecting other VeroE6-TMPRSS2 cells.
[0056] In the present specification, when "deletion of a gene" is indicated, it may be a total or partial deletion of a nucleotide sequence when the exact alteration is not indicated. It can be a deletion of any nucleotide length or also be several deletions along the nucleotide sequence, it can be any type of deletion as long as the coding protein is not functional.
[0057] According to the present invention, a "bacterial artificial chromosome" (BAC) is a DNA sequence comprising the F-factor sequence. Plasmids containing this sequence, called F-plasmids, can stably maintain heterologous sequences of a length greater than 300 kb with a maximum of one or two copies per cell. The corresponding BACs can be any known in the state of the art.
[0058] The term “virus-like particles” (or VLPs) is used to characterize a particle comprising a polynucleotide and associated proteins, both derived from SARS-CoV-2 sequences. The polynucleotide is preferably an RNA polynucleotide that encodes a replication-competent and propagation-deficient deletion mutant of SARS-CoV-2. The VLP further comprises structural proteins required for viral assembly and for infection of additional cells. Insofar as these structural genes were deleted from the propagation-deficient polynucleotides of the present invention, the VLPs of the invention are obtained using cell lines, containing the viral genes as part of the genome of the cell, which cell lines are capable of complementing these proteins. SARS-CoV and SARS-CoV-1 are synonymous and both terms refer to the first SARS- CoV that emerged in 2002.
[0059] The term "coronavirus" is used according to the present invention to refer to a group (Family) of viruses having a single molecule of linear, positive-sense, single stranded ssRNA of 25 to 33 kb. The term coronavirus includes any member of the family Coronaviridae, preferably Orthocoronaviridae, and more preferably of the genus Betacoronavirus and even more preferably SARS-CoV-2.
[0060] In the present specification "genes encoding genus-specific accessory proteins" are those genes in the coronavirus genome that encode the synthesis of proteins that are most frequently not incorporated into the virus structure.
[0061] In the present specification "expression vector" can be a bacterial artificial chromosome (BAC), a cosmid and / or a P1 -derived artificial chromosome.
[0062] The term “polynucleotide” or "nucleic acid" as used in this description refers to nucleotide sequences consisting of at least 100 nucleotides and includes genes or gene fragments, as well as, in general, any DNA or RNA molecule, single or double stranded.
[0063] In the present specification, the term "replicon" is synonymous with "RNA replicon" and refers to an RNA polynucleotide that is replication-competent as described above (since it can make many copies of itself), but defective in propagation as described above. The replicon is an RNA polynucleotide. Insofar as the present application characterizes the replicon by reference to a DNA polynucleotide sequence provided in the sequence listing it is to be understood that the replicon is in fact characterized by the corresponding RNA sequence. For example, a replicon comprising the sequence of SEQ ID NO: 2 is a replicon comprising an RNA sequence that corresponds to the DNA sequence of SEQ ID NO: 2.
[0064] The replicon of the present invention can form virus-like particles (VLPs) formed from subgenomic RNAs which act as messenger RNAs and are translated into proteins that assemble into structures giving rise to VLPs which wrap the RNA replicon. Proteins required to produce VLPs which are not encoded in the replicon must be provided in trans. In the present specification, the expression "inducing protection", should be understood as inducing an immune response in the recipient organism, mediated by antigens generating a long-term memory effect therein, said antigen being encoded by the RNA replicon of the invention. This immune response may be enhanced by mechanisms involving the induction of substances that enhance the humoral response mediated by antibodies, or cellular, mediated by interleukins, cytokines, interferons, or the like, and substances that mediate intracellular processes that cause the subject to be protected against infections caused by infectious agents.
[0065] The term "vaccine" and "vaccine composition" are synonyms having the usual meaning in the field.
[0066] The expression "comprising the gene coding for..." means, in the present disclosure, that the polynucleotide sequence gives rise to a functional viral protein. Regardless of the fact that said sequence may have undergone alterations (point mutations, deletions or additions) with respect to the canonical sequence of said gene. Similarly, RNA replicons of the present invention which are characterized as not comprising “sequences suitable for expressing” a specified ORF protein are RNA polynucleotides which do not contain sequences that would provide for a respective protein to be expressed by the RNA polynucleotides in cell culture under conditions, where WT SARS-CoV-2 would express the corresponding ORF protein.
[0067] Coronavirus genes are named as ORF (open reading frame) plus a number. In the present specification, when a coronavirus gene is mentioned, the number can be or not preceded with ORF: i.e. ORF3, gene 3.
[0068] In the present specification the number "3" within the name of an RNA replicon or an attenuated virus comprises gene 3a and 3b. These 2 genes can also be referred as 3ab.
[0069] In the present specification the number "7" within the name of an RNA replicon or an attenuated virus comprises genes 7a and 7b. These 2 genes can also be referred as 7ab.
[0070] In the present specification rSARSCoV-2 and its derivatives, refers to the different recombinant viruses obtained from SARS-CoV-2 genome in the laboratory, they could be wild type (wt), attenuated viruses (with the deletions in genes that do not make the virus propagation deficient) or replicons. Polynucleotides Encoding SARS-CoV-2 Deletion Mutants
[0071] The present invention discloses replication-competent propagation-deficient polynucleotides derived from SARS-CoV-2 genome that have been constructed by the novel combination of specific sets of deleted genes. Based on an exhaustive analysis of the effect of deleting specific genes of this virus on its replication and virulence in humanized transgenic mice models, novel combinations of deleted genes were selected to analyse their attenuation and induction of protection. In particular, the present invention provides polynucleotides comprising sequences derived from the SARS-CoV- 2 genome, which polynucleotides can be used for producing advantageous SARS-CoV- 2 vaccines.
[0072] In a first aspect the invention provides polynucleotides comprising:
[0073] (a) a polynucleotide sequence of SEQ ID NO: 42 (SARS-CoV-2A[3, E, 6 and 7] mutant) or of 43 (SARS-CoV-2A[3, E, 7 and 8] mutant); or
[0074] (b) a variant of SEQ ID NO: 42 or a variant of SEQ ID NO: 43, wherein the variant has at least 96 % identity, preferably at least 97 %, at least 98 % or at least 99 % identity to SEQ ID NO: 42 or SEQ ID NO: 43.
[0075] In a preferred embodiment the invention provides polynucleotides comprising a variant of SEQ ID NO: 42 or a variant of SEQ ID NO: 43, wherein the variant has at least 99 % identity to SEQ ID NO: 42 or SEQ ID NO: 43.
[0076] In one aspect the polynucleotide of the invention can additionally be characterized in that:
[0077] (b1) the variant encodes a replication-competent mutant of the SARS-CoV-2 RNA genome, wherein replication-competent means that the mutant SARS-CoV-2 RNA genome can produce copies upon transfection of VeroE6-TMPRSS2 cells; and
[0078] (b2) the variant encodes a propagation-defective mutant of the SARS-CoV-2 RNA genome, wherein propagation-defective means that upon transfection of VeroE6- TMPRSS2 cells the mutant SARS-CoV-2 RNA genome is not able to assemble a virus or a VLP on the basis of the proteins encoded in the variant polynucleotide, which virus or VLP would be capable of infecting other VeroE6-TMPRSS2 cells.
[0079] In a related aspect, the polynucleotide can further be characterized in that: (c) upon infection or transfection of a VeroE6-TMPRSS2 cell culture the mutant SARS-CoV-2 RNA genome is able to produce a viral titre of at least 103FFU / ml or a viral titre of at least 104FFU / ml (Focus Forming Units / ml) or at least 105FFU / ml or at least 106FFU / ml.
[0080] FFU (or Focus Forming Units) are determined using the focus forming assay, which is a immunoassay detecting infected host cells and infectious virus particles. The method comprises steps, wherein about 5 x 104VeroE6-TMPRSS2 cells are seeded per well in 96-well plates in 100 pL of media, the cells are infected with undiluted virus, and infected cells are detected after one day using immunofluorescence. Example 2.4 provides further details of one alternative of carrying out the method.
[0081] The present invention further provides variants of the above polynucleotides encoding replication-competent and propagation-defective mutants of the SARS-CoV-2 RNA genome, wherein the variants comprise the following further mutations to improve safety of the viral vector or to increase viral titer in the production process:
[0082] (1) in one Example, the present invention further provides polynucleotides comprising a variant of SEQ ID NO: 42 or a variant of SEQ ID NO: 43, which comprises a deletion of at least 18 consecutive nucleotides in the sequence encoding a full-length nsp1 domain consisting of nucleotides 266 to 805 of SEQ ID NO: 42 or SEQ ID NO: 43. The nsp1 protein controls translation and deletion of amino acids in this region has been shown to be particularly advantageous for further attenuation and thus improved safety of the use of the polynucleotides as vaccines. Deleting consecutive polynucleotides from the nsp1 sequence is illustrated in Example 2.1 , below.
[0083] (2) The present invention also provides polynucleotides comprising a variant of SEQ ID NO: 42 or a variant of SEQ ID NO: 43, which comprises a deletion of at least 6 consecutive nucleotides in the sequence encoding a furin cleavage site consisting of nucleotides 23603 to 23617 of SEQ ID NO: 42 or SEQ ID NO: 43. Examples of respective variants include SEQ ID NO: 51 (D614G and AFCS mutant) and SEQ ID NO: 53 (D614G, AFCS and KR mutant). Again, deleting parts of the furin cleavage site will significantly improve the safety of the use of the polynucleotides as vaccines.
[0084] (3) The present invention further provides polynucleotides comprising a variant of SEQ ID NO: 43 or a variant of SEQ ID NO: 42, which comprises a double mutation R203K / G204R in the Nucleocapsid (N) protein and potentially in addition to the D614G in the S protein and / or the AFCS mutant of the S protein. An example of a respective variant SEQ ID NO: 52 (D614G and R203K / G204R mutant) and a further variant is SEQ ID NO: 53 (D614G and R203K / G204R and AFCS mutant).
[0085] (4) The present invention also provides polynucleotides comprising a variant of SEQ ID NO: 43 or a variant of SEQ ID NO: 42, which comprises a sequence encoding an miRNA sequence. miRNA sequences or micro RNAs are short polynucleotides molecules known to regulate gene expression. In the present invention immunomodulatory miRNAs can be used to regulate immunological pathways such as immunosenescence and inflammageing in hosts. Examples of immunomodulatory miRNAs are SEQ ID NO: 54 (miRNA138), SEQ ID NO: 55 (miRNA155), SEQ ID NO: 56 (miRNA181a) and SEQ ID NO: 57 (miRNA223).
[0086] Due to the number of mutations introduced in the variants described in the above embodiments (1) to (4), these variants may have a lower degree of identity to SEQ ID NO: 42 or 43 and the sequence identity to SEQ ID NO: 42 or 43 is preferably in the range of at least 85%, more preferably in the range of at least 88% or at least 89%.
[0087] The advantageous features of the polynucleotides can also be combined and in one aspect the invention provides polynucleotides comprising:
[0088] (a) a polynucleotide sequence of SEQ ID NO: 42 (SARS-CoV-2A[3, E, 6 and 7] mutant) or SEQ ID NO: 43 (SARS-CoV-2A[3, E, 7 and 8] mutant); or
[0089] (b) a variant of SEQ ID NO: 42 or a variant of SEQ ID NO: 43, wherein the variant has at least 98 % identity to SEQ ID NO: 42 or SEQ ID NO: 43, and wherein the polynucleotide or the variant comprises a deletion of at least 18 consecutive nucleotides in the sequence encoding a full-length nsp1 domain consisting of nucleotides 266 to 805 of SEQ ID NO: 42 or SEQ ID NO: 43; and / or wherein the polynucleotide or the variant comprises a deletion of at least 6 consecutive nucleotides in the sequence encoding a furin cleavage site consisting of nucleotides 23603 to 23617 of SEQ ID NO: 42 or SEQ ID NO: 43.
[0090] In a particularly preferred embodiment the present invention provides a polynucleotide comprising the sequence of SEQ ID NO: 53 (SARS-CoV-2A[3, E, 6 and 7] mutant comprising the D614G, AFCS and KR mutations), which in addition to the sequence of SEQ ID NO: 53 contains one of the miRNA sequences of SEQ ID NO: 54 (miRNA138), SEQ ID NO: 55 (miRNA155), SEQ ID NO: 56 (miRNA181a) and SEQ ID NO: 57 (miRNA223). In this polynucleotide he miRNA sequence is inserted at a position of the coronaviral genome of SEQ ID NO:53 so that the resulting polynucleotide comprises SEQ ID NO:53 and the sequence of one of SEQ ID NO: 54 (miRNA138), SEQ ID NO: 55 (miRNA155), SEQ ID NO: 56 (miRNA181a) and SEQ ID NO: 57 (miRNA223).
[0091] The polynucleotide can be an RNA or a DNA polynucleotide and has a length of at least 100 nucleotides. The polynucleotide preferably has a length of less than 30 kb.
[0092] Methods for producing polynucleotides in general are well known in the art and can be used for producing the polynucleotides of the present invention. Respective methods are also illustrated in Examples 1 and may comprise steps of producing a full-length infectious cDNA clone of the SARS-CoV-2 viral RNA genome by dividing the cDNA corresponding to the SARS-CoV-2 genome into a number of fragments, chemically synthesizing the fragments and cloning the fragments stepwise into a bacterial artificial chromosome (BAG). In the BAG, the viral genomic cDNA can be flanked by a promoter, such as the CMV promoter. The viral genomic DNA can further be flanked by a ribozyme sequence, such as the hepatitis delta virus ribozyme sequence together with the bovine growth hormone polyadenylation and termination signals. These additional sequences will facilitate expression of the viral RNA from the cDNA BAG.
[0093] Based on the full-length infectious cDNA clone of the SARS-CoV-2, viral RNA genome deletion mutants can be produced. In a first step DNA fragments can be generated by chemical synthesis, which fragments contain SARS-CoV-2 polynucleotide sequences, wherein one or several viral genes were deleted (deletions are illustrated in Table 3, below; and in Figures 2 and 4). The fragments containing deletions are then inserted into the BAG sequence.
[0094] Virus-like Particles
[0095] The present invention also provides virus-like particles comprising polynucleotides of the invention as described above.
[0096] In accordance with the disclosure of the present invention, the virus-like particles (VLPs) comprise a polynucleotide of the present invention as described above, preferably an RNA polynucleotide, as well as structural proteins required to assemble a virus and infect additional cells. Insofar as these structural genes were deleted from the polynucleotides of the present invention, the VLPs of the invention are produced in cell lines, changing the respective viral genes as part of the cellular genome and thus capable of complementation.
[0097] Methods of producing VLPs are well known in the art and illustrated in Example 8. These methods can be used to produce the VLPs of the present invention. These methods may for example comprise steps of:
[0098] (a) transfecting a cell with an expression vector according to claim 11 , wherein the cell expresses a protein encoded by the ORF3a gene comprising SEQ ID NO: 6 or SEQ ID NO: 58 (codon-optimized 3a gene) and a polypeptide encoded by ORF E gene comprising SEQ ID NO: 7 or SEQ ID NO: 59 (codon-optimized E gene); and
[0099] (b) purifying the VLPs from the supernatant.
[0100] Expression Vectors
[0101] The present invention further provides expression vectors comprising a DNA sequence comprising a polynucleotide of the present invention. Any type of expression vector is encompassed by the invention, including plasmids and bacterial artificial chromosomes (BACs). The use of BACs for cloning SARS-CoV-2 viral genomic sequences is illustrated in Example 1. Numerous plasmids that can advantageously be used as expression vectors are known in the field and also illustrated in the Examples.
[0102] Cells
[0103] The present invention provides cells comprising polynucleotides of the present invention and / or an expression vector of the present invention and / or a VLP of the present invention.
[0104] The host cell may be of prokaryotic or eukaryotic origin. The examples show that the initial cloning of the viral genome was carried out using BACs and E. coli cells.
[0105] The examples also illustrate infection and transfection of eukaryotic host cells, in particular using one of the following cell lines: Vero E6 cells, Vero E6-TMPRSS2 cells, BHK21 cells. It is well known that Vero cells do not express IFN and Vero cell lines are therefore well known and frequently used for maintaining viral sequences. These cell lines can be commercially obtained from numerous sources, including depository authorities. VeroE6-TMPRSS2 cells used in the Examples of the present application were obtained from the Centre For AIDS Reagents (National Institute for Biological Standards and Control, United Kingdom). Insofar as a host cell is used for the production of VLPs using a polynucleotide encoding a SARS-CoV-2 deletion mutant of the present invention, the genome of the host cell comprises the sequences deleted from the viral genome so that the host cell is capable of complementing the structural proteins in the sense of providing the same for assembly of VLPs. In one aspect the present invention provides host cells, which express at least the SARS-CoV-2 genes of ORF3a and ORF E to allow production of VLPs. Accordingly, the host cell can contain:
[0106] • a sequence encoding ORF 3a comprising SEQ ID NO: 6 (3a gene) or a sequence comprising SEQ ID NO: 58 (codon-optimized 3a gene); and
[0107] • a sequence encoding ORF E comprising SEQ ID NO: 7 (E gene) or a sequence comprising SEQ ID NO: 59 (codon-optimized E gene).
[0108] The codon-optimized ORF3a gene and the codon-optimized ORF E gene cause less toxicity than the wild-type proteins and thus provide higher viral titers, when used for VLP production.
[0109] Vaccines
[0110] The present invention provides vaccine compositions comprising a polynucleotide of the present invention or a VLP of the present invention. The composition may further comprise pharmaceutically acceptable excipients and / or chemical or biological adjuvants or stimulants. Respective excipients, adjuvants and immunostimulants are well known in the art and can be used for this purpose.
[0111] In a preferred embodiment the vaccine composition comprises a VLP of the present invention.
[0112] In one aspect, the invention provides vaccines comprising a VLP comprising a polynucleotide variant of SEQ ID NO: 43 or a variant of SEQ ID NO: 42, wherein the variant has at least 99 % identity to SEQ ID NO: 43 or SEQ ID NO: 42.
[0113] In a related aspect, the invention provides vaccines, comprising a VLP comprising a polynucleotide comprising:
[0114] (a) a polynucleotide sequence of SEQ ID NO: 43 (SARS-CoV-2A[3, E, 7 and 8] mutant) or SEQ ID NO: 42 (SARS-CoV-2A[3, E, 6 and 7] mutant); or
[0115] (b) a variant of SEQ ID NO: 43 or a variant of SEQ ID NO: 42, wherein the variant has at least 98 % identity to SEQ ID NO: 43 or SEQ ID NO: 42, and wherein the polynucleotide or the variant comprises a deletion of at least 18 consecutive nucleotides in the sequence encoding a full-length nsp1 domain consisting of nucleotides 266 to 805 of SEQ ID NO: 43 or SEQ ID NO: 42; and / or wherein the polynucleotide or the variant comprises a deletion of at least 6 consecutive nucleotides in the sequence encoding a furin cleavage site consisting of nucleotides 23603 to 23617 of SEQ ID NO: 43 or SEQ ID NO: 42.
[0116] In a particularly preferred embodiment the present invention provides a vaccine comprising a VLP which comprises a polynucleotide comprising the sequence of SEQ ID NO: 53 (SARS-CoV-2A[3, E, 6 and 7] mutant comprising the D614G, AFCS and KR mutations), which in addition to the sequence of SEQ ID NO: 53 contains one of the miRNA sequences of SEQ ID NO: 54 (miRNA138), SEQ ID NO: 55 (miRNA155), SEQ ID NO: 56 (miRNA181a) and SEQ ID NO: 57 (miRNA223).
[0117] The vaccines can be used for protecting a patient, preferably a human patient, against subsequent SARS-CoV-2 infection. The vaccine can be formulated for topical, intranasal, oral, subcutaneous, or intramuscular administration.
[0118] The vaccine composition can be administered repeatedly. According to one aspect, the vaccine composition is administered at least two times in an interval of at least three weeks.
[0119] Brief Description of the Figures
[0120] Figure 1 : SARS-CoV-2 genome scheme and fragments used for producing polynucleotides of the invention. The upper panel scheme represents SARS-CoV-2 genome, wherein the letters above the boxes indicate viral genes: S, spike protein coding gene; E, envelope protein coding gene; M, membrane protein coding gene; N, nucleocapsid protein coding gene. The numbers, with or without letters, above the boxes indicate genusspecific genes. The construct is flanked by cytomegalovirus promoter (CMV) at the 5’ end, and hepatitis delta virus ribozyme (Rz) plus bovine growth hormone polyadenylation and termination sequences (BGH) at the 3’ end. pA, poly A tail. Grey letters indicate the silent mutations engineered as genetic markers: A20085>G, generating a unique SanDI restriction site, and G26840>C, eliminating Mlul and BsiWI restriction sites. Black letters indicate the unique restriction sites used for genome fragment assembly, their position in the viral genome is in brackets. pBAC-SARS- CoV-2 sequence is described in SEQ ID NO: 8.
[0121] The scheme in the lower panel represents the six fragments (F1 to F6) designed to engineer SARS-CoV-2 cDNA, flanked by the restriction sites selected for the assembly. Fragment size, in nucleotides (nt), is indicated below the arrows.
[0122] Figure 2: Structural overview over SARS-CoV-2 human coronavirus genome and polynucleotides encoding SARS-CoV-2 deletion mutants. Representation of the genome of SARS-CoV-2 strain Wuhan-Hu-1 (WU- WT, GenBank MN908947, SEQ ID NO: 1) and of the constructed SARS- CoV-2 deletion mutants (WU-A[3], WU-A[E], WU-A[3,E], WU-A[3,E,7,8], WU-A[3,E,6,7]). The letters above the boxes indicate viral genes: Swuhan, spike protein coding gene of strain Wuhan-Hu-1 ; E, envelope protein coding gene; M, membrane protein coding gene; N, nucleocapsid protein coding gene. The numbers, with or without letters, above the boxes indicate the genus-specific genes 3a, 6, 7a, 7b, 8, 9b. UTR, untranslated region; ORF, open reading frame; An, poly A tail. The last construct contains two encircled areas highlighting the domain of the nsp1 protein coding sequence, which can be modified by deletion of nucleotides, and the furin cleavage site which can also be modified by deletions in addition to the deletions introduced into the constructs comprising A[3,E,7,8] and A[3,E,6,7] polynucleotides. Genes 3a and E, and selected from the genes 6, 7a, 7b, and 8. Numbers above the boxes indicate the nucleotide position in the genome. The right panel provides information on the replication and self-propagation competence of the genome / replicon.
[0123] Figure 3: Expression of SARS-CoV-2 3a and E proteins encoded by pTRE-E, pTRE-3a, pLVX-E and pLVX-3a plasmid (Example 2.3). Detection of SARS-CoV-2 3a and E proteins by Western Blot analysis. Cell lysates were resolved by SDS-PAGE (NuPAGE™ 4-12% Bis-Tris Gel, Invitrogen by Thermo Fisher Scientific, USA) and transferred to PVDF membranes (Immun-Blot PVDF Membranes for Protein Blotting, BIO-RAD, USA) with a Mini Gel Tank electroblotting apparatus (Invitrogen by Thermo Fisher Scientific, USA) at 80V for two hours. Membranes were blocked for an hour at room temperature with 3% dried skimmed milk in T-TBS (TBS + 0.1 % Tween 20) and then probed with the following primary antibodies: rabbit anti-E bleeding (diluted 1 :500) and sheep anti-3a bleeding (diluted 1 :1000) overnight at 4°C in T-TBS containing 1% dried skimmed milk. Bound primary antibodies were detected with horseradish peroxidase conjugated goat anti-rabbit IgG (Ref. A0545, Sigma-Aldrich, Madrid, Spain) and rabbit anti-sheep (Ref. 31480, Invitrogen by Thermo Fisher Scientific, USA) diluted 1 :10000 in T-TBS with 1% dried skimmed milk, followed by incubation with the Clarity™ Western ECL Substrate (BIORAD, USA), according to the manufacturer’s recommendations.
[0124] Figure 4: Structural overview over SARS-CoV-2 and polynucleotides encoding SARS-CoV-2 deletion mutants with two, three or four deleted genes (produced in Example 2). The dashed areas represent the deleted genes from SARS-CoV-2 Wll-WT to obtain the deletion mutants. The right panel indicates that all deletion mutants can be rescued. RNA replicons missing genes 3a and E are replication-competent, propagation-defective, and those in which two additional genes have been deleted among the three genes 6, 7a-7b or 8 are, in addition, attenuated in relation to the wild type RNA replicon. Deletion mutants were engineered using the SARS- CoV-2 cDNA clone from our lab. Viral genes are indicated at the top of the figure. White boxes within discontinuous lines represent deleted genes. The sequence of SARS-CoV-2 parental virus (wt) and the respective deletion mutants in which two genes 3 & E, (A[3,E]), or four genes: 3, E, 7, 8 (A[3,E,7,8] or A[3,E,6,7]) have been deleted, is shown. Additionally, nsp1 protein and furin cleavage site in the Spike protein can be eliminated to increase safety in A[3,E,7,8], A[3,E,6,8] & A[3,E,6,7] mutants. Viability shown on the right side of the Figure.
[0125] Figure 5: Rescue and stability of SARS-CoV-2, SARS-CoV-2 A[3,E], SARS- CoV-2A[3,E,7,8], SARS-CoV-2A[3,E,6,8], SARS-CoV-2A[3,E,6,7] in VeroE6-TMPRSS2 cells. Virus titers for the passage numbers pO, p1 , p2, p4 are shown. RNA replicons in which four genes were deleted, that provided the highest titers were selected for further characterization (SARS-CoV-2 A[3,E,7,8] and SARS-CoV-2 A[3,E,6 7] based on their highest virus titers and higher number of deleted genes. Figure 6: The SARS-CoV-2A[3,E], SARS-CoV-2A[3,E,7,8] and SARS-CoV- 2A[3,E,6,7] RNA replicons are propagation-deficient in mice lungs (Example 5). Six 21-week-old female K18-hACE2 transgenic mice were intranasally inoculated with 104FFU / animal of each RNA replicon. Lung samples were obtained at 3- and 6-days post-infection and viral titers were determined (n = 3 mice per time point). The figure shows that in the absence of complementation by providing the deleted proteins in trans, the RNA replicons were not detected at days 3 or 6 post infection. The values represent means of 9 mice. Error bars indicate SEM.
[0126] Figure 7: Reverse transfection increases titers of the SARS-CoV-2A[3,E,6,7] RNA replicon in VeroE6-TMPRSS2 cells (Example 3). Comparison of VLP titer in the rescue of the RR-WU-Swu- A[3,E,6,7] mutant using direct or reverse transfection and providing 3a and E protein in trans. Supernatants were collected after 72 hours post transfection (hpt) and titrated by immunofluorescence technique as previously described (Gutierrez et al., 2021). Vertical bars represent the mean and the standard deviation of the data obtained in the lung of each of the three mice used for each experimental setting. Unpaired t test: *, p < 0.05. Results are represented as the mean ± SD. *, p < 0.05.
[0127] Figure 8: Viral stocks of the SARS-CoV-2-A[3,E], SARS-CoV-2-A[3,E,7,8],
[0128] SARS-CoV-2-A[3,E,6,7] RNA replicons in VeroE6-TMPRSS2 cells (Example 4). Stock generation of RNA replicons- WU-Swu-(A[3,E], - A[3,E,7,8] and -A[3,E,6,7]). Vero E6-TMPRSS2 were infected with each mutant at a MOI of 0.001 , and 3a and E proteins were provided in trans. Supernatants were collected at 72 hpi and were non-concentrated (NC) or concentrated (C) using the Intact Virus Precipitation Reagent (optimized for SARS-CoV-2) (Invitrogen. Ref: 10720D). VLPs stocks were titrated by immunofluorescence technique. The vertical bars represent the mean and the standard deviation of the data. Results are represented as the mean ± SD. Figure 8 shows that high titer can be obtained by high expression or concentration
[0129] Figures 9-11 : Details of protection experiments performed in mice to determine the efficacy of the immunization by the RNA replicons developed. Figure 12: SARS-CoV-2-A[3,E], SARS-CoV-2-A[3,E,7,8], SARS-CoV-2-A[3,E,6,7] RNA replicons induced generation of spike-specific and RBD- specific IgG antibodies in immunized mice. Serum samples from immunized and non-immunized mice, were collected at 21 dpi and analyzed (n = 4 mice). Mice were immunized with the indicated RNA replicons encapsidated inside virus like particles (VLPs) derived from SARS-CoV-2. The absorbance (420 nm), provided by serum samples diluted 1 :100, obtained by ELISA plate reader. The figure illustrates IgG levels. Results are represented as the mean ± SD.
[0130] Figure 13: SARS-CoV-2-A[3,E], SARS-CoV-2-A[3,E,7,8], SARS-CoV-2-A[3,E,6,7] RNA replicon induced neutralization of SARS-CoV-2 WU-WT. Mice were immunized with the indicated RNA replicons encapsidated inside virus like particles (VLPs) derived from SARS-CoV-2. Serum samples from immunized and non-immunized mice, collected at 21 dpi were analyzed (n = 4 mice / assay). Serum samples diluted from 1 :5 to 1 :160 were incubated with 100 PFU of SARS-CoV-2 WU-WT. Results are represented as the mean ± SD. Results are illustrated in Figure 13 and show that neutralization is more discriminatory than identification of specific antibodies as shown.
[0131] Figure 14: Specific T-Cell response against a pool of SARS-CoV-2 antigens. Mice were either immunized with SARS-CoV-2-A[3,E], SARS-CoV-2- A[3,E,7,8], or SARS-CoV-2-A[3,E,6,7] replicons encapsidated inside virus like particles (VLPs) derived from SARS-CoV-2, or mock-immunized. To analyze the immune response to the VLP replicons, mice were sacrificed at 21 days post-immunization, and the CD8+ / TNFa+ and CD8+ / IFNy+ T- cell responses generated against a pool of peptides from the spike protein, were analyzed by flow cytometry. The SARS-CoV-2 S protein peptide pools used in the immunogenicity analysis (PM-WCPV-S-2. PepMix™ SARS-CoV-2 Spike Glycoprotein) were purchased from J PT Peptide Technologies (Berlin, Germany). JPT The S peptide pools were distributed in two groups spanning the S1 and S2 regions of the S protein, with each peptide pool containing 158 (S1) or 157 peptides (S2) as consecutive 15-mers overlapping by 11 amino acids. Bronchoalveolar lavage cells (BAL) were treated with RPMI 10% FBS (negative control) or a pool of antigens. This result showed a clearly activated and expanded population of cytotoxic T-Cells specific for SARS-CoV-2 antigens. C-, tissue culture media (RPMI); SMN, peptide pool from S1 and S2 proteins.
[0132] Figure 15-16: Attenuation of SARS-CoV-2-A[3,E], SARS-CoV-2-A[3,E,7,8],
[0133] SARS-CoV-2-A[3,E,6,7] in transgenic hACE2 mice. Mice were mock inoculated (black squares) or inoculated intranasally with 104PFU of one of the three replicons (n = 4 mice). Weight loss and survival rate were daily monitored. The values indicate the mean value ± SEM. The results show that whereas WT virus induced important weight losses and that all mice died after infection, all those administered with the three RNA replicons administered as VLPs survived, indicating their safety.
[0134] Figure 17-18: Protection conferred by SARS-CoV-2-A[3,E], SARS-CoV-2-
[0135] A[3,E,7,8], SARS-CoV-2-A[3,E,6,7] in transgenic hACE2 mice. Mice were mock inoculated (black squares) or inoculated intranasally with 104PFU of one of the three replicons. After 21 days, mice were challenged intranasally with 105PFU / mice of the virulent SARS-CoV-2 virus. Weight loss and survival rate were daily monitored. The values indicate the mean value ± SEM. Results showed that 100% of the mice immunized only once with RNA replicons SARS-CoV-2-A[3,E] and SARS-CoV-2-A[3,E,7,8] survived, and 75% of mice administered SARS-CoV-2-A[3,E,6,7] also survived. In contrast, 100% of the non-immunized mice died.
[0136] Figure 19: Structural overview over SARS-CoV-2 replicon comprising sequences encoding an S protein from Omicron or Delta variant of SARS-CoV-2. Schematic representation of the wild-type SARS-CoV-2 virus (upper panel) and polynucleotides containing 4 deletions as well as Omicron (middle panel) or Delta (bottom panel) S genes.
[0137] Figure 20 Structure of ORF3a and E proteins in pcDNA3.1 plasmids
[0138] The constitutive expression vector contains a cytomegalovirus promoter at the 5’ region, followed by the mammalian codon-optimized gene of interest (ORF3a or Envelope gene). Figure 21 Expression of SARS-CoV-2 0RF3a and E proteins from pcDNA3.1 plasmids
[0139] Detection of SARS-CoV-2 ORF3a and Envelope proteins by Western Blot analysis. Cell lysates were resolved by SDS-PAGE (NuPAGETM 4-12% Bis-Tris Gel, Invitrogen by Thermo Fisher Scientific, USA) and transferred to PVDF membranes (Immun-Blot PVDF Membranes for Protein Blotting, BIO-RAD, USA) with a Mini Gel Tank electroblotting apparatus (Invitrogen by Thermo Fisher Scientific, USA) at 80V for two hours. Membranes were blocked for an hour at room temperature with 5% dried skimmed milk in TBS and then probed with the following primary antibodies: rabbit anti-E bleeding (diluted 1 :1000) and sheep anti-3a bleeding (diluted 1 :1000) overnight at 4°C in TBS containing 3% dried skimmed milk. Bound primary antibodies were detected with horseradish peroxidase conjugated goat anti-rabbit IgG (Ref. A0545, Sigma-Aldrich, Madrid, Spain) and rabbit anti-sheep (Ref. 31480, Invitrogen by Thermo Fisher Scientific, USA) diluted 1 :10000 in T-TBS with 3% dried skimmed milk, followed by incubation with the ClarityTM Western ECL Substrate (BIO-RAD, USA), according to the manufacturer’s recommendations.
[0140] Figure 22 Structure of SARS-CoV-2 polynucleotides encoding deletion mutants
[0141] Genome of SARS-CoV-2 strain Wuhan-Hu-1 (WUWT.GenBank MN908947, SEQ ID NO: 1) and SARSCoV-2 deletion mutants (WU- A[3,E], WU-A[3,E,7,8], WU-A[3,E,6,7]). The letters above the boxes indicate viral genes: SWuhan, spike protein coding gene of strain Wuhan- Hu-1 ; E, envelope protein coding gene; M, membrane protein coding gene; N, nucleocapsid protein coding gene. The numbers, with or without letters, above the boxes indicate the genus-specific genes 3a, 6, 7a, 7b, 8, 9b. UTR, untranslated region; ORF, open reading frame; An, poly A tail. The last construct contains two encircled areas highlighting the domain of the nsp1 protein coding sequence, which can be modified by deletion of nucleotides, and the furin cleavage site which can also be modified by deletions in addition to the deletions introduced into the constructs comprising A[3,E,7,8] and A[3,E,6,7] polynucleotides. Numbers above the boxes indicate the nucleotide position in the genome. The right panel provides information of the replication and self-propagation competence of the genome / replicon. Figure 23 Stability and titer of the RNA replicons in relation to passage
[0142] Virus titers for the passage numbers pO, p1 , p2 and p3 are shown. RNA replicons in which four genes were deleted, that provided the highest titers were selected for further characterization (SARS-CoV-2 A[3,E,7,8] and SARS-CoV-2 A[3,E,6,7]) based on their highest virus titers and higher number of deleted genes. Results show that maximum titers were obtained by RR: SARS-CoV-2 A[3,E,6,7] and SARS-CoV-2-A[3,E,7,8], which were selected for vaccine construction. RNA replicon in which five genes were deleted (SARS-CoV-2 A[3,E,6,7,8]) was discarded as it could not be rescued from passage 1. RNA replicon SARS-CoV-2 A[3,E,6,7]* (*: transcomplemented for 6 hours instead of 16 hours with pcDNA3.1- ORF3a optimized and pcDNA3.1-E optimized in passage 0) was also excluded due to lower viral titer compared to the other two selected RNA replicons (SARS-CoV-2 A[3,E,7,8] and SARS-CoV-2 A[3, E,6,7]).
[0143] Figure 24 Optimization of VLP vaccine production by expression of proteins 3a and E using vectors pcDNA3.1-ORF3a and pcDNA3.1-E
[0144] (A) Different concentration ratios of pcDNA3.1-ORF3a and pcDNA3.1-E plasmids were transfected into Vero E6-TMPRSS2 cells grown at 95% confluence using Lipofectamine 2000 in a 1 :3 ratio of DNA to Lipofectamine 2000. Six hours later, medium containing Lipofectamine complexes was removed and replaced with fresh medium containing a determined MOI of the supernatant from the previous passage of the SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,6,7], SARS-CoV-2 A[3,E,6,7]* and SARS-CoV-2 A[3,E, 7, 8] RNA replicons. After 18, 24, 48, and 72 hours of incubation at 37°C, cell supernatants were collected and titrated by Focus-Forming Immunofluorescence Assay for the presence of infectious focus units.
[0145] (B) Representative images of isolated foci from the Focus-Forming Immunofluorescence Assay. Vero E6 cells, seeded in 96-well plates, were inoculated with serial 10-fold dilutions of the supernatants containing the VLPs. At 16 hpi, cells were fixed and immunofluorescence was performed using an antibody specific for SARS-CoV-2 N protein and a secondary antibody labeled in green. Isolated foci were detected and counted.
[0146] Figure 25 Optimization of pcDNA3.1-ORF3a and pcDNA3.1-E expression plasmid’s to increase VLP titers Different concentration ratios (1 g pcDNA3.1-ORF3a: 1 g pcDNA3.1-E, 0.5 pg pcDNA3.1-ORF3a: 0.5 pg pcDNA3.1-E, and 0.2 pg pcDNA3.1- ORF3a: 0.2 pg pcDNA3.1-E) were transfected into Vero E6-TMPRSS2 cells grown at 95% confluence using Lipofectamine 2000. Six hours later, medium containing Lipofectamine complexes was removed and replaced with fresh medium containing a determined MOI of the supernatant from the previous passage of the SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,6,7], SARS-CoV-2 A[3,E,6,7]* and SARS-CoV-2 A[3,E,7,8] RNA replicons. After 48 hours of incubation at 37°C, cell supernatants were collected and titrated by Focus-Forming Immunofluorescence Assay, ns: not statistically significant
[0147] Figure 26 Protection conferred by SARS-CoV-2-A[3,E,6,7] RNA replicon in transgenic hACE2 mice.
[0148] Four sets of 5 mice were evaluated in this experiment. The evaluation was divided in two parts, A and B, and the scheme of the evaluation is shown for part A and B at the top of each section. In part A only one immunization was performed, whereas in part B mice were immunized with two doses. Both in A and B the first set of 5 mice were mock immunized, whereas the second one was immunized as the indicated. Mice were mock inoculated or inoculated intranasally with 105PFU of one of the SARS-CoV-2- A[3,E,6,7] RNA replicon. After 21 days, sets A and B of mice were challenged intranasally with 105PFU / mice of the virulent SARS-CoV-2 virus. Three weeks after immunization group B of mice were mock immunized or immunized a second time. Weight loss and survival rate were daily monitored. rSARS-CoV-2 A[3,E,6,7] replicon evaluated in heterozygous K18-hACE2 C57BL / 6J (strain: B6.Cg-Tg(K18- ACE2)2Prlmn / J) mice; 105PFU in 40 pL of each virus were intranasally inoculated. All non-vaccinated mice infected with SARS-CoV-2 WT virus lost weight and died between 7 and 9 dpi. In contrast, mice intranasally inoculated with the rSARS-CoV-2 A[3,E,6,7] replicon survived. Together, these results demonstrated that a single immunization with 105PFU of the rSARS-CoV-2 A[3,E,6,7] replicon was sufficient to protect against lethal infection with rSARS-CoV-2 WT in highly susceptible K18-hACE2 mice. Virus inoculations were performed under anesthesia that was induced with isoflurane, and all efforts were made to minimize animal suffering. All animals were housed in a self-contained ventilated rack (Tecniplast, IT), with the light switched on at 7:30 and switched off at 19:30. The ambient temperature was 19.5-22 °C and with humidity at 35-40%. Animal protection studies were carried out under the animal permit PROEX- 146.6 / 20, approved by the Community of Madrid (Spain), and performed in biosafety level 3 facilities at CISA-INIA (Madrid). Results showed that 100% of the mice immunized with the RNA replicon survived. In contrast, 100% of the non-immunized mice died.
[0149] Figure 27A Western Blot
[0150] Proteins collected from Vero-E6 cells non-transfected (control), transfected with pTRE-Auto-rtTA-V10-E (pTRE-E for short, with E WT or different variants: F4A, T11A, F4A-T11A, T9I, T9I-T11A, N15A, V25A, E8A, R69A). Proteins collected at 24, 30 and 48 hours post-transfection (hpt).
[0151] Figure 27B E Protein Expression from Vero-E6 cells
[0152] Graphical representation of the ratio E protein expression / B-actin expression of proteins collected from Vero-E6 cells non-transfected (negative control) or transfected with pTRE-E, with E WT or different variants: F4A, T11A, F4A-T11A, T9I, T9I-T11A, N15A, V25A, E8A, R69A). Proteins collected at 24, 30 and 48 hours post-transfection (hpt). Protein expression was quantified using Fiji software: the intensity of each E protein band was divided by the intensity of its corresponding B-actin control, obtaining a ratio (represented in the Y axis).
[0153] Figure 28 Growth kinetics of SARS-CoV-2 mutants in VeroE6 cell line
[0154] Titers (PFU / ml) of SARS-CoV-2-D614G, SARS-CoV-2-D614G-A[FCS], SARS-CoV-2-D614G-KR and SARS-CoV-2-D614G-A[FCS]-KR mutants at 24 hpi, 48 hpi and 72 hpi. VeroE6 cells were infected with a MOI of 0.01 and titers were calculated by plaque formation assay.
[0155] Figure 29 Growth kinetics of SARS-CoV-2 mutants in VeroE6-TMPRSS2 cell line
[0156] Titers (PFU / ml) of SARS-CoV-2-D614G, SARS-CoV-2-D614G-A[FCS], SARS-CoV-2-D614G-KR and SARS-CoV-2-D614G-A[FCS]-KR mutants at 24 hpi, 48 hpi and 72 hpi. VeroE6-TMPRSS2 cells were infected with a MOI of 0.01 and titers were calculated by plaque formation assay. Figure 30 Recombinant SARS-CoV-2-A[6,7,8] cDNA comprising immunomodulatory miRNAs
[0157] Accessory genes 6, 7a, 7b and 8 were deleted from the viral genome and replaced by an expression cassette comprising the transcriptionregulating sequences (TRS) of gene 7a and miRNA precursor sequences.
[0158] Figure 31 Growth kinetics of recombinant SARS-CoV-2-A[6,7,8] viruses encoding immunomodulatory miRNA-155, 181 a, 223 and 138 in Vero- TMPRRS2 (left panel) and human lung Calu3 (right panel) cells.
[0159] No significant differences either in growth kinetics or viral titers were observed for recombinant viruses encoding miRNA precursors as compared to the parental virus.
[0160] Figure 32 Expression of immunomodulatory miRNAs by recombinant SARS- CoV-2-A[6,7,8] viruses in human lung Calu3 cells
[0161] Calu 3 cells were infected (MOI= 0.01) by recombinant SARS-CoV-2- A[6,7,8] viruses encoding precursors of miRNA-155 (A), 181a (B), 223 (C) or 138 (D). Small RNAs were analyzed by Northern-blot as described above.
[0162] Figure 33 Expression of immunomodulatory miRNAs by recombinant SARS- CoV-2-A[6,7,8] viruses in Vero-TMPRRS2 cells.
[0163] Vero-TMPRRS2 cells were infected (MOI= 0.001) by recombinant SARS- CoV-2-A[6,7,8] viruses encoding precursors of miRNA-155 (A), 223 (B), 181a (C) or 138 (D). Small RNAs were purified from cells at 30 h postinfection, using mirVana miRNA isolation kit, and analyzed by Northernblot, using specific probes. U6 small nucleolar RNA was used as a loading control. miR-93 was used as an endogenous control miRNA.
[0164] EXAMPLES
[0165] 1) ENGINEERING AN INFECTIOUS FULL-LENGTH cDNA OF SARS-CoV-2 VIRUS GENOME
[0166] The first requirement for the assembly of an RNA replicon derived from SARS-CoV-2 is the construction of a full-length infectious cDNA clone of the virus. The organization of viral genes in a coronavirus (CoV) genome is: 5’ untranslated region (UTR) - replicase / transcriptase - spike protein (S) gene - envelope protein (E) gene - membrane protein (M) gene - nucleocapsid protein (N) gene - 3’ UTR and polyA tail. The four structural proteins (S, E, M and N) contribute to the assembly of viral particles. In addition, coronavirus genome also contains genes encoding genus-specific accessory proteins. These proteins are involved in counteracting host defenses.
[0167] The cDNA encoding SARS-CoV-2 genome, Wuhan-Hu-1 strain (GenBank accession MN908947.3; sequence shown in SEQ ID NO: 1), was divided in six fragments (F1 to F6) that were chemically synthesized by GenScript (Piscataway, NJ, USA). These fragments covered the full-length viral genome SARSCoV2-FL (Figure 1) and (Table 2).
[0168] Table 2. DNA fragments designed for SARS-CoV-2 cDNA assembly
[0169] RESTRICTION
[0170] POSITION (nt) l I to
[0171] SEQ ID SIZE _, ._ _k l_ pBAC-SARS-
[0172] N°k l^ / L_ , 5’ END 3’ END GENOME
[0173] NO: (bp)(a)CoV-2-FL(b)
[0174] SEQ ID
[0175] F1kl2 957 Asci BsiWI 1 - 346 7279 - 8235
[0176] NO: 9
[0177] SEQ ID
[0178] F2 6401 BsiWI Pmel 347 - 6747 8236 - 14636
[0179] NO: 10
[0180] SEQ ID
[0181] F3 7209 Pmel Mlul 6748 - 13956 14637 - 21845
[0182] NO: 11
[0183] SEQ ID
[0184] F4k l' „„ 6130 Mlul SanDI 13957 - 20086 21846 - 27975
[0185] NO: 12
[0186] SEQ ID
[0187] F5kl^ 5227 SanDI BamHI 20087 - 25313 27976 - 33202
[0188] NO: 13
[0189] SEQ ID
[0190] F6k l^ 4612 BamHI Rsrll 25314 - 29870 33203 - 37814
[0191] NO: 14
[0192] (a) Nucleotide numbering in agreement with GenBank sequence MN908947, where 1 is the first nucleotide.
[0193] (b) Nucleotide numbering in agreement with pBAC infectious cDNA sequence, were virus starts in nt 7890 from pBAC-SARS-CoV-2-FL (SEQ_ID 8) pBeloBACH plasmid (pBAC) is a commercially available vector and was used to clone the cDNA of SARS-CoV-2 (SEQ ID NO: 1). This plasmid (7507 bp) contains the origin of replication of E.coli, factor F (oirS), the chloramphenicol resistance gene (cat) and genes required to maintain a single copy of the plasmid per cell (parA, parB, parC and repE). This vector allows the stable maintenance of large DNA fragments in bacteria. The pBAC plasmid including the full-length cDNA of SARS-CoV-2 was named pBAC-SARS-CoV- 2-FL (SEQ ID NO: 8).
[0194] Two silent mutations were introduced as genetic markers: A20085>G, generating a unique SanDI restriction site, and G26840>C, eliminating Mlul and BsiWI restriction sites (Figure 1). These genetic markers are very useful as, according to NextStrain analysis, only a few cases (one in Egypt and two in Mexico) with the A20085>G mutation, which did not carry the other genetic marker, have been identified. And no cases with the G2684OC mutation have been identified in the more than five million SARS-CoV-2 sequences available to date.
[0195] In addition, viral genome cDNA was flanked by cytomegalovirus promoter (at the 5’ end) and the hepatitis delta virus ribozyme sequence together with the bovine growth hormone polyadenilation and termination signals (at the 3’ end) (Figure 1).
[0196] The DNA fragments were sequentially cloned into a bacterial artificial chromosome (BAG) (Almazan et al., 2000) that was used as a vector for SARS-CoV-2 genome maintenance and amplification, similarly as previously described by (Almazan et al., 2014). This BAG was amplified in Escherichia coli DH10B bacteria, non-pathogenic. All cloning steps were verified by restriction pattern and sequencing with primers designed across several regions of SEQ ID NO: 1 . An expert in the field would know how to design the appropriate primers spanning the whole nucleotide sequence.
[0197] To rescue the recombinant infectious virus, the BAG that included the full-length cDNA of the virus plus regulatory sequences was purified using the large construct kit (Qiagen), following the manufacturer’s instructions. Briefly, infectious cDNA was transfected into baby hamster kidney (BHK21) cells using Lipofectamine 2000 (ThermoFisher Scientific), following the manufacturer’s recommendations. Six hours after transfection BHK21 cells were detached from the plate and were seeded over confluent Vero E6 or VeroE6- TMPRSS2 cells, susceptible to SARS-CoV-2 infection. At 48 to 72 hours posttransfection, culture supernatant, containing the recombinant rSARS-CoV-2 virus, was collected and stored as passage 0.
[0198] 2) ENGINEERING RECOMBINANT SARS-COV-2 MUTANTS WITH DELETIONS IN ONE OR MORE GENES
[0199] DNA fragments were designed (Table 3) and chemically synthesized by GenScript (Piscataway, NJ, USA). These fragments contained the deletion of one or several viral genes. These deletions were combined to obtain different mutant viruses or replicons described below.
[0200] Table 3. DNA fragments required for the engineering of SARS-CoV-2 deletion mutants. RESTRICTION SITES
[0201] NAME SIZE (bp) <a> 5’ END 3’ END DELETION (nt) <b>
[0202] Fdel3 256 BamHI Hpal 25385 - 26206
[0203] FdelE 386 BspEI Agel 26237 - 26452
[0204] Fdel3-E 376 BamHI Agel 25385 - 26452
[0205] Fdel6 438 PpuMI BmgBI 27202 - 27367
[0206] Fdel7 1229 PpuMI Avril 27388 - 27759
[0207] Fdel7a 1310 BmgBI Avril 27388 - 27759
[0208] Fdel7b 1493 BmgBI Avril 27768 - 27876
[0209] Fdel8 644 BmgBI Avril 27888 - 28240
[0210] Fdel67 954 PpuMI Avril 27192 - 27845
[0211] Fdel78 756 PpuMI Avril 27388 - 28238
[0212] Fdel6-7-8 563 PpuMI Avril 27202 - 28239
[0213] (a) Refers to the sub-fragment within the pSL-F6-Bam-Avr intermediate plasmid, because it contains the corresponding deletions, is smaller than the full F6 sequence;
[0214] (b) In agreement with SEQ ID NO: 1.
[0215] To engineer these mutants, pBAC-F6 plasmid (Table 2) SEQ ID NO: 14 was digested with BamHI and Avril. The resulting 3296 bp fragment, containing nucleotides 25314 to 28609 from SARS-CoV-2 genome (SEQ ID NO: 1), was cloned in the same restriction sites of commercial plasmid pSL1190 (Amersham) and intermediate plasmid pSL-F6- Bam-Avr was obtained. Subsequently, each of the mutant fragments (Table 3) was cloned in the indicated restriction sites, which were unique in pSL-F6-Bam-Avr plasmid, leading to intermediate plasmids pSL-F6-del3, pSL-F6-delE, pSL-F6-del[3,E], pSL-F6- del6, pSL-F6-del7, pSL-F6-del7a, pSL-F6-del7b, pSL-F6-del8, pSL-F6-del[6,7] and pSL- F6-del[7,8] and pSL-F6-del[6,7,8], Fdel8 fragment was introduced in the BmgBI and Avril pSL-F6-del6 restriction sites, leading to plasmid pSL-F6-del[6,8], Afterwards, Fdel3-E fragment (Table 3) was introduced in BamHI and Agel restriction sites from pSL-F6-del6, pSL-F6-del7, pSL-F6-del8, pSL-F6-del[6,8], pSL-F6-del67 and pSL-F6-del78, leading to plasmids pSL-F6-del[3,E,6], pSL-F6-del[3,E,7], pSL-F6-del[3,E,8], pSL-F6-del[3, E,6,8], pSL-F6-del[3,E,6,7] and pSL-F6-del[3,E,7,8], respectively.
[0216] Each of the intermediate pSL-F6 plasmids were digested with BamHI and Avril and the inserts were cloned in the same restriction sites from plasmid pBAC-F6, leading to plasmids pBAC-F6-A3, pBAC-F6-AE, pBAC-F6-A[3,E], pBAC-F6-A[3,E,6], pBAC-F6- A[3,E,7], pBAC-F6-A7a, pBAC-F6-A7b, pBAC-F6-A[3,E,8], pBAC-F6-A[3,E,6,8], pBAC- F6-A[3,E,6,7] and pBAC-F6-A[3,E,7,8] and pBAC-F6-A[3,E,6,7,8], Finally, these plasmids were digested with BamHI and Rsrll and the inserts were introduced into the same restriction sites from SARS-CoV-2 infectious cDNA, leading to infectious clones pBAC-SARSCoV2-A3, pBAC-SARSCoV2-AE, pBAC-SARSCoV2-A[3,E], pBAC- SARSCoV2-A[3,E], pBAC- SARSCoV2-A[3,E,6], pBAC- SARSCoV2-A[3,E,7], pBAC- SARSCoV2-A[3,E,8], pBAC- SARSCoV2-A[3,E,6,8], pBAC- SARSCoV2-A[3,E,6,7] and pBAC- SARSCoV2-A[3,E,7,8],
[0217] The exact deletions of some of these mutants are in reference to SEQ ID NO: 1 :
[0218] • SARS-CoV-2-A[3] from 25385nt to 26206nt;
[0219] • SARS-CoV-2-A[E] from 26237nt to 26452nt;
[0220] • SARS-CoV-2-A3E from 25385nt to 26452nt;
[0221] • SARSCoV2-A[3,E,6,7] from 25385nt to 26452nt, and from 27192nt to 27845nt); and
[0222] • SARSCoV2-A[3,E,7,8] from 25385nt to 26452nt, and from 27388nt to 28238nt (Figures 2 and 4).
[0223] The nucleotide sequence of SARS-CoV-2-A[3] is SEQ ID NO: 15, of SARS-CoV-2-A[E] is SEQ ID NO: 16, of SARS-CoV-2-A[3,E] is SEQ ID NO: 17, of SARS-CoV-2-A[3,E,6] is SEQ ID NO: 47, of SARS-CoV-2-A[3,E,7] is SEQ ID NO: 48, of SARS-CoV-2-A7a is SEQ ID NO: 20, of SARS-CoV-2-A7b is SEQ ID NO: 21 , of SARS-CoV-2-A[3,E,8] is SEQ ID NO: 49, of SARS-CoV2-A[3,E,6,8] is SEQ ID NO: 44, of SARS-CoV2-A[3,E,6,7] is SEQ ID NO: 42 and of SARS-CoV2-A[3,E,7,8] is SEQ ID NO: 43.
[0224] 2.1 Engineering a SARS-CoV-2 derived replicon with additional small deletions in ORF1a
[0225] ORF nsp1 maps at the 5’-end of the coronavirus genome, whereas alternative attenuating deletion or those contributing to the replication-competent propagation deficient development of RNA replicons derived from SARS-CoV-2 map at distal positions of ORF 1 , which makes it very unlikely that a single recombination event could restore virulence or propagation ability, therefore increasing the safety of the RNA polynucleotides disclosed herein. Different individual or combined domains of ORF nsp1 were deleted, named A, B, C, or D, mapping at positions in the virus genome (SEQ ID NO: 1): 284nt to 307nt (A), 500 nt to 532nt (B), 629nt to 655nt (C), 728nt to 760nt (D).
[0226] We generated the deletions A to D individually or a combination of two of them, and the optimum combination to attenuate the SARS-CoV-2 were the deletion of domain nsp1- A (nsp1-A[A]), or the double deletion of domains B and D (nsp1-A[B,D]). To engineer the deletions termed nsp1-A[A] and nsp1-A[B,D], two synthetic fragments containing the nsp1 deletions were designed and chemically synthesized by Thermo Fisher Scientific, fragment Fnsp1-AA (SEQ ID NO: 45) containing nucleotides 1 to 351 of the SARS-CoV- 2 genome (SEQ ID NO: 1) with the deletion of nsp1 domain A, and fragment Fnspl- A[B,D] (SEQ ID NO: 46) containing nucleotides 346 to 6751 of SARS-CoV-2 genome (SEQ ID NO: 1) with the combined deletion of nsp1 domains B and D.
[0227] To engineer the replicons containing selected mutations in nsp1 , the Fnsp1-AA fragment was digested with Asci and BsiWI and the resulting 933bp fragment was cloned into the same sites of pBAC-SARS-CoV-2-A[3, E,6,7] ( SEQ ID NO: 42) and pBAC-SARS-CoV- 2-A[3,E,7,8] ( SEQ ID NO: 43) replicon candidates. The Fnsp1-A[B, D] fragment was digested with BsiWI and Pmel and the resulting 6335 bp fragment was cloned into the same sites of pBAC-SARS-CoV-2-A[3,E,6,7] ( SEQ ID NO: 42) and pBAC-SARS-CoV- 2-A[3,E,7,8] ( SEQ ID NO: 43) replicon candidates.
[0228] 2.2 Transfection of cDNAs and recovery of infectious virus of SARS-CoV-2 deletion mutants and replicons.
[0229] To rescue wild type viruses and deletion mutants, Vero E6-TMPRSS2 cells grown at 95% confluence in 12.5 cm2flasks were transfected with 6 pg of each cDNA clone using Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) in the proportion 1 :3 (micrograms : microliters) of ADN: Lipofectamine 2000, according to the manufacturer’s specifications. Six hours later, medium containing Lipofectamine complexes was removed and replaced by fresh medium. After 72 h incubation at 37°C, cell supernatants were harvested (passage 0), passaged once on fresh Vero E6-TMPRSS2 cells (passage 1) and then, the titers of virus stocks were determined by plaque assay on Vero E6 cells. The complete genome sequence of viral stocks was determined to confirm that recombinant viruses had been rescued correctly. Viral stocks were stored at -80 °C.
[0230] 2.3 Packaging Cell Line for Amplification of SARS-CoV-2 Deletion Mutants and replicons in vitro
[0231] In order to grow RNA replicons SARS-CoV-2-A[3,E], SARS-CoV-2 -A[3,E, 6, 7], SARS- CoV-2-A[3,E,6,8] and SARS-CoV-2-A[3,E,7,8], proteins 3a and E were provided in trans by using the expression plasmid shown in Figure 6 of PCT / EP2022 / 083289 or by stably transformed cells expressing these proteins. In order to asses if the single deletion of gene E or gene 3a would impair virus propagation, the growth kinetics of SARS-CoV-2-A[3] and SARS-CoV-2-A[E] was analyzed in Vero E6-TMPRSS2 cells at 24, 48 and 72 hpi. These mutants grew somehow slower and gave rise to lower titers (Figure 7 of PCT / EP2022 / 083289).
[0232] Two different cell lines expressing E and ORF3a genes were generated to rescue and amplify SARS-CoV-2 replicons lacking E and ORF3a genes: VeroE6-[E-IRES-ORF3a] and VeroE6-TMPRSS2-[E-IRES-ORF3a], E and ORF3a genes were cloned into a pLVX- TetOne-Puro plasmid (Takara) under the control of a tetracycline-inducible promoter (Figure 6 of PCT / EP2022 / 083289). The lentiviral vector LVX-TetOne-Puro-[E-IRES- ORF3a] was used following manufacturer instructions. VeroE6 and VeroE6-TMPRSS2 cells were transduced with LVX-TetOne-Puro-[E-IRES-ORF3a] lentiviral vector. Selection of transduced cells started 48 hours post-transduction by adding puromycin to the media. Two weeks later puromycin-resistant individual clones were isolated and amplified. Expression of E and ORF3a proteins was tested by western blot in the presence or the absence of the inductor (doxycycline) to validate the selected clones.
[0233] VeroE6 cells were provided by E. Snijder (University of Leiden, the Netherlands). VeroE6-TMPRSS2 cells were obtained from the Centre For AIDS Reagents (National Institute for Biological Standards and Control, United Kingdom). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 25 mM 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid and 4.5 g / L glucose (BioWhittaker; Lonza), supplemented with 4 mM glutamine, 1 * nonessential amino acids (Sigma-Aldrich), and 10% vol / vol fetal bovine serum (FBS; HyClone; Thermo Scientific).
[0234] VeroE6 or VeroE6-TMPRSS2 cells were grown to 95% confluence in 12.5-cm2flasks and transfected with 6 pg of each infectious cDNA clone and 18 pL of Lipofectamine 2000 (Invitrogen), according to the manufacturer’s specifications. Three independent cDNA clones were recovered of each mutant. At 6 h post-transfection (hpt), cells were washed with PBS 1X, and incubated at 37 °C for 72 h (passage 0) with fresh media. Cell supernatants were harvested and passaged two times on fresh cells (passages 1 and 2). The viability, titer, and sequence of the mutants were analyzed to generate viral stocks for in vitro and in vivo evaluations.
[0235] To rescue viruses lacking the E and ORF3a genes, VeroE6-[E-IRES-ORF3a] or VeroE6- TMPRSS2-[E-IRES-ORF3a] were transfected with SARS-CoV-2 replicon cDNAs. At 6 hpt, the medium containing the plasmid-Lipofectamine complexes was removed from the transfected cells and washed. Fresh medium supplemented with doxycycline at a concentration of 1 pg / mL was added and cells were incubated at 37 °C for 72 h. For successive virus amplification passages and virus stocks, doxycycline at a concentration of 1 pg / mL was added to VeroE6-[E-IRES-ORF3a] or VeroE6-TMPRSS2-[E-IRES- ORF3a] to induce expression of E and ORF3a genes to allow propagation of SARS-CoV- 2 replicons. Results are illustrated in Figure 3 and show that the cells express the proteins needed for complementation of the polynucleotides encoding the propagationdeficient SARS-CoV-2 deletion mutants described above.
[0236] To study growth kinetics subconfluent monolayers (90% confluence) of VeroE6, VeroE6- TMPRSS2, Huh-7 and Huh-7-ACE2 cells, or Calu-3a cells, grown in 12-well plates were infected at an MOI of 0.001 with the indicated viruses. Culture supernatants were collected at 0, 24, 48, and 72 hpi, and virus titers were determined by plaque assay.
[0237] Among the two cell lines, only VeroE6-TMPRSS2-[E-IRES-ORF3a] was selected for further analysis, since growth kinetics and titers of SARS-CoV-2-WT in VeroE6- TMPRSS2 were faster and higher, respectively. Therefore, VeroE6-TMPRSS2-[E-IRES- ORF3a] were transfected with different combination of genes deleted SARS-CoV-2- A[3,E], SARS-CoV-2-A[3,E,6,7], or SARS-CoV-2-A[3,E,7,8] replicons. At 72 hpt (passage 0) supernatants were harvested and passed once more (passage 1) to evaluate rescue, growth and amplification of this vaccine candidate.
[0238] In the absence of doxycycline (-E / -ORF3a) no SARS-CoV-2-A[3,E], SARS-CoV-2 - A[3,E,6,7], or SARS-CoV-2-A[3,E,7,8] could be detected by focus-forming immunofluorescence assay, while in its presence titers of 104and 105FFU / mL (focusforming unit) were detected at passages 0 and 1 , respectively. This result validates the system for the rescue, growth and amplification of SARS-CoV-2 replicons for its in vivo evaluation.
[0239] The cells transformed with these plasmids can thus be used to complement the deletion mutants.
[0240] 2.4 Titration of SARS-CoV-2 Replicons by Focus-Forming Immunofluorescence Assay.
[0241] In total, 5 x 104VeroE6-TMPRSS2 cells were seeded per well in 96-well plates in 100 pL of media 1 d prior to the immunofluorescence assay. The next day, cells were infected with 20 pL of undiluted or serial 10-fo Id-diluted virus. At 16 hpi, cells were fixed with paraformaldehyde 4% wt / vol for 40 min, washed, and permeabilized with chilled methanol at R / T for 20 min. Nonspecific binding was blocked with FBS 10% in PBS for 1 h at R / T. Then, cells were incubated for 90 min at R / T with rabbit monoclonal antibody anti-N-SARS-CoV / SARS-CoV-2 (SinoBiological). Secondary monoclonal antibody goat anti-rabbit conjugated with Alexa 488 (Invitrogen) was incubated for 45 min to detect and count infectious foci of SARS-CoV-2 replicons. The titer was expressed as focus-forming units (FFUs) per milliliter.
[0242] VeroE6-TMPRSS2-[E-IRES-ORF3a] were transfected with the SARS-CoV-2, SARS- CoV-2-A[3,E], SARS-CoV-2-A[3,E,7,8], SARS-CoV-2-A[3,E,6,8] or SARS-CoV-2- A[3,E,6,7] replicon. At 72 hpt (passage 0) supernatants were harvested and passed four times (passage 1 to 4) evaluating rescue, growth and amplification of this vaccine candidate. Titers were detected at passages 0, 1 , 2 and 4. The replicons characterized by four deleted genes provided the highest titers of which SARS-CoV-2-A[3,E,7,8] and SARS-CoV-2-A[3,E,6,7] were selected for further analysis (Figure 5). The results demonstrate the reproducibility and stability of the different RNA replicons during sequential passage.
[0243] 2.5 Viral Titration by Plaque Formation Assay
[0244] Vero E6 cells were seeded on 12-well plates, grown to 100% confluence and infected by duplicate with factor 10 serial dilutions of viral supernatants. After 45 min adsorption at 37°C, the inoculum was removed and cells were overlaid with DM EM supplemented with 4 mM glutamine, 1 % v / v of non-essential amino-acids, 2% v / v of FBS, 0.16 mg / ml of DEAE-Dextran and 1 % low-melting agarose. 96 hpi, cells were fixed with 10% formaldehyde and stained with 0.1 % crystal violet. The number of plaques formed in each well was determined. Titers were determined by multiplying the number of plaques in each well by the dilution factor and expressed as the number of plaque forming units (PFUs) per ml (PFU / ml).
[0245] In order to examine the stability of the SARS-CoV-2-A[3,E], SARS-CoV-2-A[3,E,6,7], or SARS-CoV-2-A[3,E,7,8] replicons in cell culture and also assess whether it could recombine with the RNA encoding E and ORF3a proteins transcribed in the packaging cell lines, RNA from cell culture was extracted, and the region between the S and N genes within the SARS-CoV-2-A[3,E,7,8] or alternative replicons was amplified by PCR and sequenced with primers WH-25155-VS (SEQ ID NO: 26) and WH-28957-RS (SEQ ID NO: 27). After 16 passages in VeroE6-[E-IRES-ORF3a] or VeroE6-TMPRSS2-[E- IRES-ORF3a], we found that it remained genetically stable with no evidence that SARS- CoV-2 replicon deletion mutants recombined with the RNA encoding the E or ORF3a proteins.
[0246] The stability of rSARS-CoV-2-nsp1-A[A] and rSARS-CoV-2-nsp1-A[B,D] mutants was analyzed in VeroE6-TMPRSS2 cells. Cells were seeded in 12.5-cm2flasks and infected with the mutant. Every 24 h, a third of the supernatant was used to infect a fresh cell monolayer. After each passage, the remaining supernatant was stored at -80 °C. Cells were lysed to extract RNA as described above. Full-length virus was sequenced to show the presence of the introduced deletion. The results indicated that after 5 passages of the virus including the deletions of part of nsp1 gene (AA or A[B,D]) the virus was competent in replication and maintained its sequence.
[0247] 2.6 Updated Spike Protein in Replicon
[0248] It is well known in the art that SARS-CoV-2 Omicron strain is prevalent in the world today. In fact, in the USA more than 90% on novel infections are caused by the Omicron strain. In addition, the observation has been made that immunization with only Omicron strains induced good protection against Omicron strains, but not against older strains. On the other hand, exclusive immunization with older strains, such as Delta, induced good protection against the infection by all earlier strains, but reduced protection against the highly evolved Omicron strain.
[0249] For this reason, a vaccine strain was produced that includes S proteins from Omicron and Delta strains. SARS-CoV-2 deletion mutant cDNAs were used to introduce the new Spike sequences (Delta and Omicron variants). First, two F4 DNA fragments were obtained by chemical synthesis (GeneScript) (F4-S Delta, SEQ ID NO: 40; and F4-S Omicron, SEQ ID NO: 41) that included nucleotides from 20084 to 25312 of SARS-CoV- 2 genome, flanked by SanDI and BamHI unique restriction sites. The fragments digested with SanDI and BamHI were introduced into the corresponding sites of plasmid pBACFL- SARS-CoV-2-A[3,E,6,7] or pBACFL-SARS-CoV-2-A[3,E,7,8], to generate the corresponding cDNA infectious clones (pBACFL-SARS-CoV-2-A[3,E,6,7]-Somicron, pBACFL-SARS-CoV-2-A[3,E,6,7]-Sdeita, pBACFL-SARS-CoV-2-A[3,E,7,8]-SOmicron and pBACFL-SARS-CoV-2-A[3,E,7,8]-Sdeita). This method can also be used for producing strains comprising S proteins from Omicron and Delta strains for other SARS-CoV-2 deletion mutants described herein. The integrity of the cloned DNA was verified by restriction pattern analysis and by Sanger sequencing. 3) RESCUE OF RNA REPLICONS BY REVERSE TRANSFECTION
[0250] Rescue of the RNA replicon SARS-CoV-2 A[3,E,6,7] was determined when applying the direct and reverse transfection method and complementation of the 3a and E protein in trans. Application of the reverse transfection method leads to increased RNA replicon titers compared to the direct transfection method.
[0251] In total, 5 x 104 VeroE6-TMPRSS2 cells were seeded per well in 96-well plates in 100 pL of media 1 d prior to the immunofluorescence assay. The next day, cells were infected with 20 pL of undiluted or serial 10-fo Id-diluted virus. At 16 hpi, cells were fixed with paraformaldehyde 4% wt / vol for 40 min, washed, and permeabilized with chilled methanol at R / T for 20 min. Nonspecific binding was blocked with FBS 10% in PBS for 1 h at R / T. Then, cells were incubated for 90 min at R / T with rabbit monoclonal antibody anti-N-SARS-CoV / SARS-CoV-2 (SinoBiological). Secondary monoclonal antibody goat anti-rabbit conjugated with Alexa 488 (Invitrogen) was incubated for 45 min to detect and count infectious foci of SARS-CoV-2 replicons. The titer was expressed as focus-forming units (FFUs) per milliliter.
[0252] 4) GENERATION OF VIRUS TITER STOCK OF CONCENTRATED SARS-COV-2 VLPS
[0253] For generation of viral stocks SARS-CoV-2-A[3,E], SARS-CoV-2-A[3,E,7,8], SARS-CoV- 2-A[3,E,6,7] RNA replicons VeroE6-TMPRSS2 were infected at MOI 0.001 and the 3a and E proteins provided in trans. The supernatants were recovered at 3 dpi and further processed using the Intact Virus Precipitation Reagent (Invitrogen) according to manufacturer’s instructions to obtain a non-concentrated (NC) and concentrated (C) VLP stock. VLP stocks were titrated by immunofluorescence technique as described above. Results are represented as the mean ± SD (Figure 8).
[0254] 5) EVALUATION OF GROWTH AND VIRULENCE OF SARS-CoV-2 DELETION MUTANTS IN VIVO.
[0255] The attenuation of the mutants was evaluated in K18-hACE2 C57BL / 6J mice (strain 2B6.Cg-Tg(K18-ACE2)2Prlmn / J, 20-26-week-old) obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were mock inoculated or inoculated intranasally with 104PFU of the SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,7,8] or SARS-CoV-2 A[3,E,6,7] replicons. Five mice were used for monitoring the disease and six for lung sample collection at days 3 and 6 post-infection (n=3 mice at each time point). Body weight and survival of infected mice were monitored for 10 days. Animals suffering weight losses as much as 20% of the initial weight were sacrificed according to the established end point criteria. At days 3 and 6 post-infection, three mice from each experimental group were sacrificed by cervical dislocation for lung sampling. Half of the right lung was collected for viral titer determination, and stored at -80 °C until use. The rest of the lung was stored in RNAIater solution (Sigma-Aldrich) for 48 h at 4°C for RNA extraction and stored at -80°C until further processing to guarantee the integrity of the RNA molecules. The left lung was fixed in a 10% zinc formalin solution (Sigma-Aldrich) for 24-48 hours at 4°C for virus inactivation and subsequent histopathological analysis.
[0256] To determine viral titers, lungs were homogenized in 2 mL of PBS containing 100 lll / mL penicillin, 0.1 mg / mL streptomycin, 50 pg / mL gentamicin, and 0.5 pg / mL amphotericin B (Fungizone) using a gentleMACS dissociator (Miltenyi Biotec, Inc.). Virus titrations were performed in VeroE6-TMPRSS2 cells as described above. Viral titers were expressed as PFU counts per gram of tissue. All work with infected animals was performed in an Animal Biosafety Level 3+ laboratory wearing personal protection equipment (3M).
[0257] 5.1 Lifespan and Weight
[0258] The pathogenicity of SARS-CoV-2-A[3,E], -A[3,E,6,7], -A[3,E,7,8] replicons was evaluated in K18-hACE2 mice. SARS-CoV-2 was used as the reference virulent virus (WT); 1 x 104PFU of virus or replicon were intranasally inoculated into mice, and weight loss and survival were monitored for 14 days.
[0259] At days 3 and 6 post-infection, three mice from each experimental group were sacrificed by cervical dislocation for lung sampling. Half of the right lung was collected for viral titer determination, and stored at -80 °C until use. The rest of the lung was stored in RNAIater solution (Sigma-Aldrich) for 48 h at 4°C for RNA extraction and stored at -80°C until further processing to guarantee the integrity of the RNA molecules. The left lung was fixed in a 10% zinc formalin solution (Sigma-Aldrich) for 24-48 hours at 4°C for virus inactivation and subsequent histopathological analysis.
[0260] The results showed severe weight losses for mice infected with SARS-CoV-2 WT. However, mice infected with the SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,7,8], SARS- CoV-2 A[3,E,6,7] replicons maintained weight over the 14 days post-infection. Survival rate of mice was additionally monitored showing death of all mice after 8 days post- infection when infected with SARS-CoV-2 WT. By contrast, mice infected with the RNA replicons lead to a survival rate of 100 % over the 14 days post-infection.
[0261] Full attenuation and thus safety of the SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,7,8], SARS-CoV-2 A[3,E,6,7] replicons was demonstrated. The results showed that the replicons of the invention cause no pathology to the mice model used in the experiments and thus demonstrate safety when administered (Figure 15, Figure 16). The safety was further demonstrated by the absence of propagation polynucleotides in immunized mice lungs (Figure 6).
[0262] 5.2 Replication, Transcription and Propagation
[0263] To further characterize infected mice, virus titer or RNA levels were analyzed in lungs at 3 and 6 dpi. High virus titers were determined at 3 and 6 dpi in the lungs of mice infected with SARS-CoV-2-WT virus or the indicated deletion mutants.
[0264] To analyze safety of the replicons, 21 -week-old K18-hACE-2 transgenic mice were either infected with SARS-CoV-2 WU-WT or with SARS-CoV-2 A[3,E], SARS-CoV-2 A[3, E,7,8] or SARS-CoV-2 A[3,E,6,7], High virus titers were detected at 3 and 6 dpi in the lungs of mice infected with SARS-CoV-2 WU-WT virus, but no virus growth was observed in the lungs of mice inoculated with the SARS-CoV-2-A[3,E], SARS-CoV-2-A[3,E,7,8], SARS- CoV-2-A[3,E,6,7] replicons. In the absence of external complementation of the protein 3 and protein E, the constructed replicons did not spread from cell to cell. While the SARS- CoV-2 A[3,E], SARS-CoV-2 A[3,E,7,8] and SARS-CoV-2 A[3,E,6,7] were stably maintained in the cell (Figure 5), they cannot be propagated from one cell to another cell (Figure 6). The replicons of the present invention are thus considered to be propagationdefective, replication-competent RNA replicons.
[0265] The results therefore show that SARS-CoV-2 deletion mutants replicated in the sense of producing further RNA polynucleotides without spreading to other cells.
[0266] 5.3. Extraction and Purification of RNA from Lung Samples
[0267] Lung samples were removed from the RNA storage solution and homogenized in 2 ml of RLT lysis buffer (Qiagen, Germany) with 1 % v / v B-mercaptoethanol (Sigma-Aldrich) using a gentleMACS Dissociator homogenizer (Miltenyi Biotec), according to the manufacturer's instructions. The homogenized samples were centrifuged at 3000 rpm for 10 minutes at 4° C. Then, total RNA was purified from the supernatant using the RNeasy Mini Kit reagent (Qiagen). 5.4 Synthesis of cDNA from RNA by Reverse Transcription (RT) cDNAs were synthetized by reverse transcription using the High-Capacity cDNA transcription kit (Applied Biosystems, USA), following the manufacturer's recommendation. 100 - 150 ng of total lung RNA were used as template and random hexamers as primers in a reaction volume of 20 l. cDNA products were subsequently subjected to PCR for sequencing using Vent polymerase (New England Biolabs). cDNA products from mouse lungs were analyzed by real-time quantitative PCR (qPCR) for viral RNA synthesis quantification. SARS-CoV-2 genomic RNA (forward primer 5'- GTGARATGGTCATGTGTGGCGG-3', SEQ ID NO: 28 reverse primer 5'- CARATGTT AAA SA CACTATTAGC ATA-3', SEQ ID NO: 29 and MGB probe 1 5'- CAGGTGGAACCTCATCAGGAGATGC-3' SEQ ID NO: 30) and SARS-CoV-2 subgenomic messenger RNA (sgmRNA) N (forward primer 5'- CCAACCAACTTTCGATCTCTTGT-3', SEQ ID NO: 31 reverse primer 5-
[0268] 'GGGTGCATTTCGCTGATTTT-3', SEQ ID NO: 32 and MGB probe 2 5'- TTCTCTAAACGAACAAACTA-3' SEQ ID NO: 33) custom probes were designed for this analysis; forward and reverse primers were purchased from Sigma-Aldrich, and MGB probes were purchased from Eurofins Genomics. Data were acquired with a QuantStudio 5 Real-Time PCR system (Applied Biosystems) and analyzed with ABI PRISM 7500 software, version 2.0.5. The relative quantifications were performed using the cycle threshold (2-AACT) method. To normalize differences in RNA sampling, the expression of mouse 18S ribosomal RNA was analyzed using a specific TaqMan Gene Expression Assay (Mm03928990_g1 ; ThermoFisher Scientific).
[0269] 5.5 Lung Histopathology
[0270] Mice were euthanized at the indicated day postinfection (dpi) or day postchallenge (dpc). The left lungs of infected mice were fixed in 10% zinc formalin for 24 h, at 4 °C and paraffin embedded. Serial longitudinal 5-pm sections were stained with hematoxylin and eosin by the Histology Service at CNB-CSIC (Madrid, Spain) and subjected to histopathological examination with a ZEISS Axiophot fluorescence microscope. Samples were obtained using a systematic uniform random procedure, consisting of serial parallel slices made at a constant thickness interval of 50 pm. Histopathology analysis was conducted in a blind manner by acquiring images of 50 random microscopy fields from around 40 nonadjacent sections for each of the three independent mice analyzed per treatment group. No significant pathological changes were observed in the lungs of mice infected with SARS-CoV-2-A[3,E,6,7] or SARS-CoV-2-A[3,E,7,8] at 3 dpi. In contrast, the lungs of mice infected with SARS-CoV-2-WT virus showed clear alveolar wall thickening and peribronchial cuffing. By 6 dpi, examination of lungs of SARS-CoV-2-infected mice revealed generalized infiltration and parenchyma consolidation, as well as edema in the airspaces, whereas the lungs of mice infected with SARS-CoV-2-A[3,E,6,7] or SARS- CoV-2-A[3,E,7,8] replicon remained similar to those of uninfected mice.
[0271] 6) HUMORAL AND CELLULAR RESPONSE IN IMMUNIZED MICE ELICITED BY SARS-CoV-2 RNA REPLICON DELETION MUTANTS.
[0272] 6.1 Indirect Enzyme-Linked ImmunoSorbent Assay (ELISA)
[0273] Serum samples from mice immunized with SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,7,8] or SARS-CoV-2 A[3,E,6,7] or mock-immunized were collected at 21 days postimmunization (dpi). Samples were diluted to 1 :100. Spike protein-specific IgG antibody levels and RBD-specific (receptor binding domain-specific) IgG antibody levels were measured by Indirect Enzyme-Linked ImmunoSorbent Assay (ELISA).
[0274] 96-well Nunc Maxisorp immune plates (Thermo Scientific) were coated with 100 ng / well of SARS-CoV-2 RBD protein. The protein was diluted in PBS at a final concentration of 2 pg / ml in 50 pl per well. The plates were incubated at 4 °C for 24 hours.
[0275] Unbound protein was removed, ELISA plates were washed three times with PBS-0.05% Tween20 (PBST) and 200 pl of PBST-3% milk (blocking buffer) were added. Plates were incubated for 1.5 hours at room temperature. Meanwhile, serum samples were inactivated at 56 °C for 30 minutes and serial dilutions were prepared in PBST-1% milk. 50 pl of diluted sera were added to the wells and the plates were incubated for 2 hours at room temperature. Plates were washed with PBST, secondary HRP-conjugated goat anti-mouse IgG and IgA (Southern Biotech), depending on the evaluated antibody isotype, were diluted in PBST-1 % milk according to manufacturer instructions and 50 pl / well were added. After 1 hour incubation at room temperature, plates were washed and 50 pl of supersensitive TMB were added. The plates were incubated at room temperature in darkness approximately 5-10 minutes and the reaction was stopped with 0.5 M H2SO4. Optical density was read at 450 nm with a ELISA plate reader (Tecan).
[0276] Results are shown in Figure 12 and illustrate high levels of anti-spike and anti-RBD IgG were detected in immunized mice (21 dpi) for all tested replicons. The specific response against SARS-CoV-2 detected in the serum, strongly demonstrates that the SARS-CoV- 2-A[3,E], SARS-CoV-2-A[3,E,7,8], SARS-CoV-2-A[3,E,6,7] polynucleotides will provide immunity against subsequent viral infection.
[0277] 6.2. Plaque Reduction Neutralization test (PRNT50)
[0278] Vero-E6 cells were seeded in 24-well tissue culture plates 24 hours prior to neutralization. The serum samples from mice immunized with SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,7,8] or SARS-CoV-2 A[3,E,6,7] or from non-immunized mice were inactivated 56 °C for 30 minutes, serial dilutions of these serum samples were prepared with 2% FBS DM EM and incubated for 1 hour at 37 °C with 50 PFU of SARS-CoV-2 in 1 :1 volume proportion. The mixture serum:virus was added to the pre-seeded 24-well plates and were incubated for 1 hour at 37 °C. The overlay medium (2x DMEM with 1% agarose) was prepared and added to the plates, which were incubated for 3 days in 5% CO2 37 °C incubator. The cells were fixed with 10% formaldehyde solution and stained with crystal violet.
[0279] Neutralizing antibodies were measured by 50% plaque reduction neutralizing test (PRNT50), considering the neutralizing antibody titer as the highest serum dilution that reduce 50% the number of plaques in comparison to the plaques formed by the only virus. Neutralizing antibodies against SARS-CoV-2 Wll-WT were not detected in nonimmunized groups, whereas serum samples from immunized mice at 21 dpi neutralized SARS-CoV-2 Wll-WT with a neutralization capacity (TCID50) of > 8 (Figure 13).
[0280] 6.3. Cellular Immune Response in Mice Immunized with SARS-CoV-2 RNA Polynucleotides
[0281] To assess whether the SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,7,8], SARS-CoV-2 A[3,E,6,7] replicons are able to elicit a cellular immune response, K18-hACE2 mice were intranasally immunized with the SARS-CoV-2 replicons and sacrificed after 15 days. Lungs of mice were flushed with RPMI medium supplemented with HEPES, - mercaptoethanol, and L-glutamine. Cellular debris were removed by centrifugation and lung samples stored at -20°C.
[0282] The immune responses of CD-4+ and CD-8+ T-cells were analyzed by ICS as previously described (Garcia-Arriaza et al, 2021 ; Perez et al., 2022) with some modifications. Collected cells were seeded on plates and stimulated for 24 hours in RPMI 10% FBS and the SARS-CoV-2 S1 and S2 peptide pools (1mg / ml). Cells were washed and stained for analysis. Specific fluorochrome-conjugated antibodies were used for functional analysis (CD3-phycoerythrin (PE)-CF594, CD4-allophycocyanin (APC)-Cy7, CD8-V500, IFN-g-PE-Cy7, TNF-a-PE, and IL-2-APC) and phenotypic analysis (CD62L-Alexa Fluor 700 and CD127-peridinin chlorophyll protein (PerCP)-Cy5.5). Cell analysis was conducted by flow cytometry. Data analysis was performed with the FlowJo software.
[0283] Immune response of T-cells in bronchoalveolar lavages of immunized mice was evaluated by analyzing the percentages of CD-4+ or CD-8+ T-cells with double expression of tumor necrosis factor alpha (TNFa) and interferon gamma (IFNy) cytokines. The results showed high percentages of CD-8+ T-cells expressing TNFa and IFNy in the samples of mice immunized with the different replicons, as compared to mock, and high percentages of double positive cells were only shown when samples were stimulated with the SARS-CoV-2 peptide pool (S1 and S2). Percentages of CD-8+ cells with expression of TNFa and IFNy in SMN-stimulated samples of mice immunized with SARS-CoV-2 replicons were: SARS-CoV-2 A[3,E] 41.2%, SARS-CoV-2 A[3,E,6,7] 52.5% and SARS-CoV-2 A[3,E,7,8] 21.4% (Figure 14).
[0284] 7) PROTECTION ELICITED BY SARS-CoV-2-[3,E], -A[3,E,6,7], and A[3,E,7,8] POLYNUCLEOTIDES IN VIVO
[0285] The same protocols described in Example 3, above, was used in this Example. 16- to 24-week-old female mice were anesthetized with isoflurane and intranasally inoculated with 50 pL of virus diluted in DMEM. SARS-CoV-2 and its deletion derived replicons were evaluated using 10,000 PFU of the indicated virus per mouse to assess virulence and 100,000 FFU of virulent SARS-CoV virus in challenge experiments. Weight loss and mortality were evaluated daily. To determine viral titers, lungs were homogenized in 2 mL of PBS containing 100 lU / mL penicillin, 0.1 mg / mL streptomycin, 50 pg / mL gentamicin, and 0.5 pg / mL amphotericin B (Fungizone) using a gentleMACS dissociator (Miltenyi Biotec, Inc.). Virus titrations were performed in VeroE6 or VeroE6-TMPRSS2 cells as described above. Viral titers were expressed as PFU counts per gram of tissue. All work with infected animals was performed in an Animal Biosafety Level 3+ laboratory wearing personal protection equipment (3M).
[0286] K18-hACE2 mice (23-week-old) were immunized by administrating the RNA replicons SARS-CoV-2 A[3,E], SARS-CoV-2 A[3, E,7,8], SARS-CoV-2 A[3,E,6,7] as VLPs or mock immunized. After three weeks post-immunization, mice were challenged with a lethal dose of SARS-CoV-2 WT (105PFU / animal). Body weight and survival rate of infected mice were monitored for 14 days. Animals suffering weight losses as much as 20% of the initial weight were sacrificed according to the established end point criteria. In contrast to mock-immunized mice, immunized mice started to recover normal body weight at day 6 post- infection and reached a body weight of > 90 % of initial body weight. Survival rates were additionally monitored showing protection of mice when immunized with one of the three replicons. Non-immunized mice lost weight and died between 6 and 8 dpc (Figure 17 and Figure 18). However, mice immunized with SARS-CoV-2 A[3,E,6,7] showed 75 % protection and mice immunized with SARS-CoV-2 A[3,E] or SARS-CoV-2 A[3,E,7,8] showed 100 % protection.
[0287] These results demonstrated that SARS-CoV-2 A[3,E], SARS-CoV-2 A[3,E,7,8] and SARS-CoV-2 A[3,E,6,7] replicons induced high protection levels in K18-hACE2 mice against a lethal dose of SARS-CoV-2 WT virus. The results indicate the SARS-CoV-2 A[3,E,7,8] replicon showing 100 % protection as a promising candidate for vaccine development.
[0288] 8) PRODUCTION OF A VACCINE FOR SARS-CoV-2 BASED ON DEFECTIVE RNA REPLICONS (RR) BY COMPLEMENTATION IN TRANS WITH THE DELETED VIRUS PROTEINS PROVIDED BY A CONSTITUTIVE EXPRESSION SYSTEM (pcDNA3.1)
[0289] 8.1. pcDNA3.1 Vector
[0290] A commercially available vector pcDNA3.1 (from Invitrogen) was used for constitutive expression of mammalian codon-optimized Envelope and ORF3a proteins of SARS- CoV-2. pcDNA3.1 plasmid contains 5428 bp, including a cytomegalovirus promoter (CMV) at the 5’ region, followed by the gene of interest (Figure 20). The sequence of the resulting construct was verified through Sanger sequencing (Macrogen) of the purified plasmids.
[0291] To generate these expression vectors, synthetic fragments (GenScript) of the optimized mammalian sequences of the ORF3a gene (828 pb) (SEQ_ID_58) and Envelope gene (225 pb) (SEQ_ID_59) were assembled, flanked by unique-site restriction enzymes (BamHI and Xbal in the ORF3a gene) and (BamHI and Notl in the Envelope gene). These synthetic fragments were subsequently cloned into the pcDNA3.1 vector using the BamHI (located in the multiple cloning site), Notl, and Xbal restriction sites.
[0292] The correct orientation of the inserts in the vector was verified by PCR using: - An internal oligonucleotide (ORF3a opt RS: 5’-TTTGTGTGCCAACACAGG-3’) and an external (CMV VS: 5’-GTCGTAACAACTCCGCCC-3’) with respect to the inserted ORF3a fragment.
[0293] - An external oligonucleotide (CMV VS: 5’-GTCGTAACAACTCCGCCC-3’) with respect to the inserted Envelope fragment.
[0294] To assess the functionality of these expression vectors, SARS-CoV-2 ORF3a and Envelope proteins were detected in cell lysates via Western Blot analysis (Figure 21). Cell lysates were resolved by SDS-PAGE (NuPAGETM 4-12% Bis-Tris Gel, Invitrogen by Thermo Fisher Scientific, USA) and transferred to PVDF membranes (Immun-Blot PVDF Membranes for Protein Blotting, BIO-RAD, USA) with a Mini Gel Tank electroblotting apparatus (Invitrogen by Thermo Fisher Scientific, USA) at 80V for two hours. Membranes were blocked for an hour at room temperature with 5% dried skimmed milk in TBS and then probed with the following primary antibodies: rabbit anti-E bleeding (diluted 1 :1000) and sheep anti-3a bleeding (diluted 1 :1000) overnight at 4°C in TBS containing 3% dried skimmed milk. Bound primary antibodies were detected with horseradish peroxidase conjugated goat anti-rabbit IgG (Ref. A0545, Sigma-Aldrich, Madrid, Spain) and rabbit anti-sheep (Ref. 31480, Invitrogen by Thermo Fisher Scientific, USA) diluted 1 :10000 in T-TBS with 3% dried skimmed milk, followed by incubation with the ClarityTM Western ECL Substrate (BIO-RAD, USA), according to the manufacturer’s recommendations.
[0295] 8.2. Transfection of cDNAs and recovery of SARS-CoV-2 RNA replicons with the pcDNA3.1 expression system and mammalian codon-optimized ORF3a and E envelope genes
[0296] To rescue the deletion mutants, BHK21 cells grown at 95% confluence in 100 mm cell culture dishes were transfected with 1 pg of the RNA replicon and 0.5 pg of the constitutive expression vectors pcDNA3.1 -optimized ORF3a and pcDNA3.1 -optimized E, using Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) in a 1 :3 ratio (micrograms:microliters) of ADN: Lipofectamine 2000, according to the manufacturer’s specifications.
[0297] Six hours later, medium containing Lipofectamine complexes was removed, and BHK21 cells were detached and seeded onto a cellular monolayer of Vero E6-TMPRSS2 cells grown at 95% confluence in 100 mm cell culture dishes, previously trans-complemented between 6-16 hours with the constitutive expression vectors pcDNA3.1 -optimized ORF3a and protein E (1 pg of each plasmid) using Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) in a 1 :3 ratio (micrograms:microliters) of ADN: Lipofectamine 2000, according to the manufacturer’s specifications. After 48 hours of incubation at 37°C, RNA, protein extracts, and cell supernatants were collected and stored at -20°C (RNA and protein extracts) and -80°C (cell supernatants), or analyzed by PCR (RNA), Western Blot (protein extracts), or titrated by Focus-Forming Immunofluorescence Assay (cell supernatants).
[0298] 8.3. Stability and titer of a collection of SARS-CoV-2 derived RNA replicons as vaccines
[0299] A collection of SARS-CoV-2 deletion mutants was engineered as described above. The following deletion mutants were engineered, and evaluated: SARS-CoV-2-A[3,E], SARS- CoV-2 A[3, E,6,7], SARS-CoV-2-A[3,E,7,8] or SARS-CoV-2-A[3,E,6,7,8] (Figure 22).
[0300] The titer and stability of the engineered replicons were determined after several passages in cell culture including each of the deletion RNA replicons engineered in order to assess their correct sequence. For this purpose, Vero E6-TMPRSS2 cells were grown at 95% confluence in 100 mm cell culture dishes were trans-complemented with the constitutive expression vectors pcDNA3.1-with an optimized ORF3a and pcDNA3.1 with an optimized protein E (1 pg of each plasmid), using Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) in a 1 :3 ratio of DNA to Lipofectamine 2000, according to the manufacturer’s specifications.
[0301] Six hours later, medium containing Lipofectamine complexes was removed and replaced with fresh medium containing a determined MOI of the supernatant from the previous passage.
[0302] After 48 hours of incubation at 37°C, RNA, protein extracts, and cell supernatants were collected and stored at -20°C (RNA and protein extracts) and -80°C (cell supernatants), or analyzed by PCR (RNA), Western Blot (proteins), or titrated by Focus-Forming Immunofluorescence Assay (cell supernatants).
[0303] The RR produced in cell culture was extracted, and the region between the S and N genes within the RNA replicons was amplified by PCR and sequenced with primers WH- 25155-VS (SEQ ID NO: 26) and WH-28957-RS (SEQ ID NO: 27). The results indicated that after 3 passages of the RNA replicons, were competent in replication and maintained their sequence (Figure 4A- and B).
[0304] To evaluate the titers of the VLPs, 5x104VeroE6 cells were seeded per well in 96-well plates in 125 pL of media one day prior to the immunofluorescence assay. The next day, cells were infected with 20 pL of undiluted or serial 10-fold— d i I uted virus from the previous passage. At 16 hours post- infection at 37 °C, cells were fixed with paraformaldehyde 4% for 50 min, washed with PBS 1x, and permeabilized with chilled methanol at room temperature for 20 min. Nonspecific binding was blocked with FBS 10% in PBS 1x for 1 hour at room temperature. Then, cells were incubated for 120 minutes at room temperature with rabbit monoclonal antibody anti-N-SARS-CoV / SARS-CoV-2 (SinoBiological). Secondary monoclonal antibody goat anti-rabbit conjugated with Alexa 488 (Invitrogen) was incubated for 45 minutes to detect and count infectious foci of SARS-CoV-2 RNA replicons. Replicon RNA titers were expressed as focus-forming units (FFUs) per milliliter and were evaluated at passages 0, 1 and 2. The results are represented as the mean ± SD (Figure 23A and 23B). The results indicated that maximum titers were obtained by RR: SARS-CoV-2 A[3,E,6,7] and SARS-CoV-2- A[3, E,7,8], which were selected for vaccine construction.
[0305] 8.4. Optimization of the VLP vaccine production by the expression of proteins 3a and E using vectors pcDNA3.1-ORF3a and pcDNA3.1-E
[0306] VLPs were collected at different times and also produced in the presence of different proportions of these proteins in order to select optimum experimental condition. The complementation provided by pcDNA3.1 as a source of proteins 3a and E has been used to optimize the rescue of our RNA replicons, and the concentration of pcDNA3.1-ORF3a and pcDNA3.1-E plasmids transfected into VeroE6 TMPRSS2 cells has also been optimized. Additionally, the optimal post-infection harvesting time of the supernatants to obtain the optimum VLP titer has also been analyzed. Different ratios (1 , 0.5, or 0.2 ratios) of pcDNA3.1-ORF3a and pcDNA3.1-E (Figure 24A) were transfected into Vero E6-TMPRSS2 cells grown at 95% confluence using Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) in a 1 :3 ratio of DNA to Lipofectamine 2000, according to the manufacturer’s specifications. Six hours later, medium containing Lipofectamine complexes was removed and replaced with fresh medium containing a determined MOI of the supernatant from the previous passage. After 18, 24, 48, and 72 hours of incubation at 37°C, protein extracts and cell supernatants were collected and subjected to analysis. Protein extracts were analyzed by Western Blot (data not shown), while cell supernatants were titrated by Focus-Forming Immunofluorescence Assay for the presence of infectious focus units (Figures 24A and 24B). To achieve the highest VLP titers, the supernatants were collected at 48 hours post-infection.
[0307] Despite the lack of relevant differences in VLP titers obtained when the RR with deletions the deletions SARS-CoV-2 A[3,E,6,7], and SARS-CoV-2-A[3,E,7,8] complemented with different concentrations of pcDNA3.1 expression vectors (Figure 25), there is a general trend of higher titer levels when the RR were complemented with the highest concentrations permitted by the Lipofectamine 2000, according to the manufacturer’s specifications (1 pg pcDNA3.1-ORF3a: 1 pg pcDNA3.1-E). Optimal conditions for complementation and rescue were achieved by using the pcDNA3.1 in VeroE6 TMPRSS2 cells at concentrations of 1 pg per expression vector and collecting cell supernatants at 48 hours post-infection.
[0308] Immunization of Mice against SARS-CoV-2 using RNA Replicons Rescued With pcDNA3.1 Expression System
[0309] The experiment in vivo was evaluated in K18-hACE2 mice (strain B6.Cg-Tg(K18- ACE2)2Prlmn / J, 22-week-old). Three sets of five mice each were used:
[0310] (i) For first group, five mice were mock inoculated;
[0311] (ii) the second group was intranasally immunized on day one with one dose of 105PFU of the SARS-CoV-2 A[3,E,6,7] RNA replicons administered as VLPs;
[0312] (iii) the third group was intranasally immunized on day one and one week later, i.e. , twice, with one dose of 105PFU of the SARS-CoV-2 A[3,E,6,7] RNA replicons administered as VLPs.
[0313] Body weight and survival of infected mice were monitored for 14 days in groups one and two, and for an additional week in the case of third group. Animals suffering weight losses as much as 20% of the initial weight were sacrificed according to the established end point criteria.
[0314] Non-vaccinated mice showed severe weight losses when infected with SARS-CoV-2 WT. Immunized mice with one or two doses, were fully protected from challenge (Figure 26).
[0315] All non-vaccinated mice died within 8 days post-infection with SARS-CoV-2 WT. By contrast, mice immunized with one or two doses with the RNA replicons led to a survival rate of 100 % over the 14 days post-infection (Figure 26). RNA replicons administered as VLP vaccines, rescued using pcDNA3.1 constitutively expressing proteins 3a and E provided full protection. The results further show that the replicons of the invention do not cause side effect in mice, indicating that the RNA replicons were safe (Figure 26).
[0316] In contrast to mock-immunized mice, immunized mice started to recover normal body weight at day 6-7 post-infection and reached a body weight of > 90 % of initial body weight (Figure 26). Survival rates were additionally monitored showing protection of mice when immunized with one of the three RNA replicons. Nonimmunized mice lost weight and died between 6-8 days post-challenge (Figure 26). However, mice immunized with RNA replicons administered as VLPs showed 100% protection. 9) REDUCTION OF E PROTEIN TOXICITY FOR INCREASING STABILITY OF SARS- CoV-2 E AND EXPRESSION LEVELS OF THE RNA REPLICON
[0317] 9.1. Aim and Concept
[0318] In order to identify combinations of deletions providing optimized RRs, different combinations of non-essential proteins for virus replication were deleted in the RRs evaluated (Figs. 2, 4) and the RRs including a set of four proteins deleted [3a, E, 6, 7] was selected (SEQ ID 42). The removal of proteins 3a and envelope (E) is responsible for the propagation-deficiency of the RR. In order to reconstitute the formation of viruslike particles (VLPs) that encapsidate the RR, the expression of proteins 3a and E in trans is essential. A main limitation in the engineering of RRs was the presence of toxic regions in different domains of the structural E protein, reducing the stability of the cells expressing E protein and negatively affecting the packaging of the RR inside VLPs. Using the subsequent methods three regions suitable for decreasing cell toxicity of the E-protein mutants were identified, leading to higher RR replicon titers and immunization levels:
[0319] A. The toxicity of specific E protein residues near the amino-terminus region. Substitutions T9I (mutation C26164>T of SEQ ID 1) and T11A (A26275>G of SEQ ID 1), were found in Omicron variants such as XBB.1.5 (Wang et al., 2023) and improve E protein expression and cell survival in vitro.
[0320] B. Formation of E protein pentameric ion channels also contributes to E protein toxicity. Ion channel toxicity was suppressed by the introducing mutation N15A (A26287>G, A26288>C of SEQ ID 1), that reduces coronavirus virulence (Nieto- Torres et al., 2014). Reduction of ion channel activity increased the stability of the cell line expressing E protein.
[0321] C. The presence of the domain formed by the last four amino acids (DLLV) of the E protein carboxy-terminus, named the PDZ binding motif (PBM), which binds to PDZ domains frequently present in mammalian cell proteins, has also been identified as a toxic domain. The substitution of the four residues by glycines (mutPBM, GGGG) caused a reduction in virulence, which also translates to a reduction in cell toxicity (Jimenez-Guardeho et al., 2014).
[0322] 9.2. Engineering of plasmids encoding SARS-CoV-2 E protein mutants
[0323] Two approaches were used: (i) expression under the control of the doxycycline-inducible vector pTRE-Auto-rtTA-V10, in which E protein expression was controlled by the induction with doxycycline, (ii) expression under the control of the constitutive expression plasmid pcDNA3.1 , with G418 selection. For both approaches, 3a and E mutants were engineered by cloning DNA fragments purchased from GeneArt (Regensburg, Germnay) into the corresponding vector (pTRE- Auto-rtTA-V10 or pcDNA3.1), using Agel and EcoRI or Kpnl and Xhol restriction enzymes, respectively (Table 4).
[0324] Table 4. DNA fragments designed for E mutants
[0325] RESTRICTION SITES
[0326] NAME PLASMID SIZE (bp)(a)5’ END 3’ END MUTATION(b)
[0327] E-WT pTRE-Auto 445 Agel EcoRI None pcDNA3.1 292 Kpnl Xhol
[0328] E-F4A pTRE-Auto 445 Agel EcoRI T26254>G, T26253>C pcDNA3.1 292 Kpnl Xhol
[0329] E-T11A pTRE-Auto 445 Agel EcoRI A26275>G pcDNA3.1 292 Kpnl Xhol
[0330] T26254>G, T26253>C,
[0331] E-F4AT11A pTRE-Auto 445 Agel EcoRI
[0332] A26275>G pcDNA3.1 292 Kpnl Xhol
[0333] E-T9I pTRE-Auto 445 Agel EcoRI C26164>T pcDNA3.1 292 Kpnl Xhol
[0334] E-T9IT11A pTRE-Auto 445 Agel EcoRI C26164>T, A26275>G pcDNA3.1 292 Kpnl Xhol
[0335] E-N15A pTRE-Auto 445 Agel EcoRI A26287>G, A26288>C pcDNA3.1 292 Kpnl Xhol
[0336] E-V25A pTRE-Auto 445 Agel EcoRI T26318>C pcDNA3.1 292 Kpnl Xhol
[0337] E-E8A pTRE-Auto 445 Agel EcoRI A26267>C pcDNA3.1 292 Kpnl Xhol
[0338] E-R69A pTRE-Auto 445 Agel EcoRI A26449>G, G26450>C pcDNA3.1 292 Kpnl Xhol
[0339] (a) Refers to the synthesized sub-fragment flanked by the indicated restriction sites, including E gene in position 195-422 (for pTRE-Auto inserts) or 23-250 (for pcDNA3.1 inserts);
[0340] (b) In agreement with SEQJD NO: 1 9.3. E protein expression under the control of the doxycycline-inducible vector pTRE-Auto-rtTA-V10
[0341] Confluent VeroE6 cells, seeded in M48 plaques, were transfected with 100 ng of the different pTRE-Auto plasmids, medium was replaced by 10% FBS-DMEM 6h posttransfection (hpt). Protein samples were collected with 50 pL of SDS-loading buffer at 24, 30 and 48 hpt, to evaluate the presence of 3a and E proteins. The amount of protein expression was analyzed by western blot as described, using as a primary antibody the mouse anti-E hybridoma 17H9 D5G8C4 in the case of E protein, produced at our institute CNB, Protein Tools Department (using a 1 :500 dilution), and as secondary antibody rabbit anti-mouse HRP (1 :10000).
[0342] High E protein expression levels were observed only in mutants with amino acid substitutions T11A, T9I, and T11A-T9I, affecting the amino terminal of E protein, or N15A, that inactivates the ion channel activity of E protein, whereas WT protein or the modification of other residues achieved low or undetectable protein levels. (Fig. 27A).
[0343] E protein levels in each case were normalized using B-actin levels, and referring them to the WT E protein levels at 24 hpt. Significant increases in E protein levels were observed for E protein mutants T9I (up to 25-fold increase at 24 hpt), T9I and T11A (75-fold increase at 30 hpt), and T11A (52-fold increase at 48 hpt). E protein mutant including N15A substitution, affecting ion channel activity, also achieved high E protein levels peaking at 30hpt (20-fold increase) (Fig.27B).
[0344] The relative amount of each E protein expression levels indicated that mutant T11 A and double mutant T9T11A, reduced E protein toxicity achieving the highest E protein expression levels. Therefore, these mutants, particularly the T11A improves complementation of the RNA replicon.
[0345] 9.4. E protein expression under the control of the constitutive expression plasmid pcDNA3.1, with G418 selection.
[0346] Confluent VeroE6 cells seeded in M96 plaques, were transfected with 50 ng of the different pcDNA3.1 plasmids. Cell selection was made with 1 mg / mL G418.
[0347] Cell viability was assessed using a MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay, in which viable cells reduce the MTT compound into formazan crystals with absorbance at 570nm, directly proportional to cell viability [4]. Briefly: medium was removed, 0,5 pg / mL MTT (in complete DMEM medium) was added to each well, after 40 min at 37°C medium was removed again and formazan crystals were dissolved in 150 pL of DMSO per well, absorbance was measured at 570nm. Absorbance levels are directly proportional to cell viability.
[0348] In a VeroE6-transfected cell line, under the control of pcDNA3.1 constitutive expression and G418-selection plasmids, E proteins containing mutations T9I, N15A or mutPBM (C- terminus substitution of the PBM motif DLLV by glycines) have higher cell viability levels than WT E protein.
[0349] Therefore, residues T9 and T11 have a role in exogenous E protein expression levels and cytotoxicity in our VeroE6 packaging cell line system; and both the ion channel activity and the PBM seem to have effects in cell toxicity as well as their previously described effects in virulence.
[0350] 10) MUTATIONS FOR IMPROVING SARS-CoV-2 DERIVED RNA REPLICON PRODUCTION FOR USE AS VACCINE
[0351] In order to increase SARS-CoV-2 derived RNA replicon production as a vaccine to prevent COVID19, three different approaches have been evaluated: (i) introduction of the mutation D614G, (ii) removal of the furin cleavage site (FCS) in the Spike (S) protein of the virus, and (iii) introduction of the double mutation R203K / G204R in the Nucleocapsid (N) protein. Data indicated that these modifications may lead to virus titer increase and, therefore, to titer increase of the RNA replicon (RR) derived from the corresponding SARS-CoV-2. To accomplish this objective, three, complementary aims are been developed:
[0352] A. Introduction of the mutation D614G in S protein of SARS-CoV-2. This mutation was naturally introduced in the virus a few months after the emergency of the SARS- CoV-2-WU virus in China, and it has been preserved in all virus variants of concern. This substitution in S protein led to a titer increase of 10-fold, in comparison to the original SARS-CoV-2, especially in human cell lines (Wang et al, 2023).
[0353] B. Introduction of the deletion of the FCS in combination with D614G substitution in S protein. The deletion of the FCS in SARS-CoV-2 has been related to a fitness increase and higher titer of the virus when passed in VeroE6 cell in relation to the wild type virus. Additionally, the loss of FCS leads to an attenuation of the virus in vivo (Johnson et al, 2021). The combination of both D614G mutation and FCS deletion in S protein showed an increase in viral titer even higher than in the case of just the point mutation alone (up to 13-fold in VeroE6 cells at 24 hours post-infection).
[0354] C. The insertion of double mutation at positions R203K / G204R of N protein, has been associated to a higher viral replication (Wu et al, 2021). In the background of the D614G mutation or in combination with the two other mutations described at points 1 and 2, the combination of the three mutations in the same N protein led to an increase of 8-fold or 28-fold in the titer of the SARS-CoV-2 virus, respectively.
[0355] 10.1. Engineering of SARS-CoV-2 infectious cDNA carrying D614G mutation
[0356] To engineer the mutant described in this Aim, overlapping PCR using plasmid pUC57-F5 (Table 2, above) as a template was performed. First, a 655 bp PCR product was amplified with oligonucleotides WH-22763-VS (5’-
[0357] GTAATTAGAGGTGATGAAG-3’) and D614G-RS (5’-
[0358] CTGTGCAGTTAACACCCTGATAAAGAACAGC-3’, A23403>G mutation in bold and underlined font), and a 1 ,788 bp PCR product was amplified using oligonucleotides D614G-VS (5’-GCTGTTCTTTATCAGGGTGTTAACTGCACAG- 3’, A23403>G mutation in bold font) and WH-25174-RS (5’-
[0359] TCCAAGTTCTTGGAGATCG-3’). Overlapping PCR product was then amplified using intermediate PCR products as templates and oligonucleotides WH-22763- VS and WH-25174-RS. The final 2,412 bp PCR product was digested with BsfEII and EcoRV and cloned into the same sites of pUC57-F5 (Table 2) to generate pUC57-F5-D614G. Finally, pUC57-F5-D614G was digested with SanDI and BamHI and cloned into the same sites of pBAC-SARSCoV2FL, to generate the pBAC-SARSCoV2FL-D614G. The genetic integrity of the cloned DNAs was verified throughout the subcloning and assembly process by extensive restriction analysis and sequencing.
[0360] 10.2. Engineering of SARS-CoV-2 infectious cDNAwith D614G mutation and removal of FCS
[0361] Plasmid pBAC-SARS2CoV2FL-D614G-A[FCS] was generated by overlapping PCR, as described in point 10.2.1 , using pBAC-SARSCoV2FL-D614G as a template. A 575 bp PCR product was amplified with oligonucleotides SARS2-S- 23043-VS (5’- CATATGGTTTCCAACCCACT- 3’) and SARS2-S-DeltaFurin-RS (5’- ACTAGCTACACTACGAGAATTAGTCTGAGT- 3’), and a 931 bp PCR product was amplified using SARS2-S-DeltaFurin-VS (5’ ACTCAGACTAATTCTCGTAGTGTAGCTAGT- 3’) and SARS2-S-24511 -RS (5’ - CAGCCTCAACTTTGTCAAGA- 3’). Overlapping PCR product was amplified using PCR products as templates and oligonucleotides SARS2-S-23043-VS and SARS2-S-24511 -RS. The 1 ,476 bp PCR product obtained was digested with BsfEII and EcoRV and cloned into the same sites of pUC57-F5 (Table 2) to generate the pUC57-F5-D614G-A[FCS], and then pUC57-F5-D614G-A[FCS] was digested with SanDI and BamHI and cloned into the same sites of pBAC- SARSCoV2FL, to generate the pBAC-SARSCoV2FL-D614G-A[FCS]. Restriction analysis and sequencing were performed to verify the genetic integrity of the cloned DNAs.
[0362] 10.3. Engineering of SARS-CoV-2 infectious cDNA with D614G mutation, 203K / 204R double mutation in the N protein, with or without FCS
[0363] A synthetic fragment of 425 bp containing 203K / 204R double mutation in the N protein was acquired from Invitrogen. This fragment was designed from Bln\ restriction site to BbvC\ restriction site and cloned into a pMA-RQ plasmid. The plasmid was digested with these restriction enzymes and cloned into the same sites of pUC57-F6, to generate the pUC57-F6-KR. Then, pUC57-F6-KR was digested with BamHI and Rsrll and cloned into the same sites of pBAC- SARSCoV2FL-D614G and pBAC-SARS2CoV2FL-D614G-A[FCS], to generate the plasmids pBAC-SARSCoV2FL-D614G-KR and pBAC-SARS2CoV2FL-D614G- A[FCS]-KR. Restriction analysis and sequencing were performed to verify the genetic integrity of the cloned DNAs.
[0364] 10.4. Increase in Viral Titers of the Engineered Mutant Viruses
[0365] In VeroE6 cells (Figure 28), significant differences in viral titer among the mutants was shown at 24 h. Whereas SARS-CoV-D614G exhibited the lowest titer of 2.53x105PFU / ml and the SARS-CoV-2-D614G-A[FCS]-KR mutant reached a titer of 7.33x106PFU / ml. Viral titers increase was highest at 48 hpi in all cases, and the mutant carrying all the modifications kept displaying the highest titer (1.07x107PFU / ml). In VeroE6-TMPRSS2 cells (Figure 29), all mutants presented similar titers at 24 hpi and 48 hpi, showing a loss of virus fitness advantage in this cell line. At 72 hpi, titers reduced considerably (up to 56-fold), whereas SARS-CoV-2-D614G-A[FCS]-KR presented almost the same titer.
[0366] Results are shown in Figures 28 and 29 and illustrate that introduction of D614G substitution, FCS deletion and R203K / G204R double mutation altogether in a single coronavirus improved viral replication and therefore virus titers 1 .5 logarithmic units when compared with wild type SARS-CoV-2 in VeroE6 cells. For vaccine production at large scale it is advisable to reach a minimum of 107PFU / ml. Another advantage of using this cell line for vaccine development is the reduction of production costs due to fast RNA replication (the highest virus titers were obtained at early times post-infection), and the lack of antibiotics, needed to keep the expression of TMPRSS-2 in VeroE6-TMPRSS2 cells. In addition, deletion of FCS enhanced genomic stability, vaccine safety and reduces polytropism of virus, and therefore the RNA replicon candidate stability.
[0367] 11) EXPRESSION OF IMMUNOMODULATORY miRNAs BY SARS-CoV-2 RNA REPLICONS
[0368] Less effective responses to vaccines are observed in the elderly because of immunosenescence and inflammageing. The effectiveness of SARS-CoV-2 vaccines is reduced in older adults, which are the more susceptible population to severe illness and death (Palacios-Pedrero et al. Nat. Ageing. 2022. https: / / doi.org / 10.1038 / s43587-022- 00292-y). To improve the efficacy of immune responses, RNA-replicons will be engineered to deliver immunomodulatory miRNAs targeting host factors that regulate immunological pathways such as immunosenescence and inflammageing.
[0369] Two major hallmarks of human immunological ageing are “inflammageing” and T-cell immunosenescence. Inflammageing is characterized by a chronic low-grade inflammation that enhances innate immunity in detriment of adaptive immunity. Elevated levels of proinflammatory cytokines negatively impact adaptive immunity, including T cell responses. Promoting T cell responses in immunosenescent individuals is expected to enhance the efficacy of vaccine candidates in the particularly vulnerable older adult population. Therefore, the incorporation of miRNAs that reduce inflammaging or immunosenescence to vaccine candidates could improve vaccine safety and efficacy in older adults.
[0370] The proof of principle for expression of immunomodulatory miRNAs from SARS-CoV-2 genomes was performed in propagation-competent viruses in which the four accessory genes (6, 7a, 7b and 8) were deleted (SEQ ID NO. 24). The mutation D614G was engineered in the viral genome to improve infectivity. In a second stage, miRNAs will be inserted into the improved final version of replication-competent propagation-deficient RNA replicons developed as vaccine candidates.
[0371] 11.1. Engineering SARS-CoV-2-A[6,7,8] encoding precursors of heterologous miRNAs pBAC-SARS-CoV-2-FL plasmid including the mutation D614G in the S protein was used as the basis for the generation of all the mutants. The accessory genes 6, 7a, 7b and 8 were deleted from the viral genome and replaced by an expression cassette including precursors of human miRNAs under the control of Transcription-Regulating Sequences (TRS) of gene 7 (TRS7).
[0372] A 667-nt DNA fragment flanked by PpuMI and Avril restriction sites was chemically synthesized (GenScript, Thermo Fisher Scientific), including the following sequence elements: the last 198 nt of SARS-CoV-2 M gene (nt 26994-27191 of SEQ ID 1), transcription-regulating requences of gene 7 (TRS7) including the core sequence (CS) and 20 nt of each 5’ and 3’ TRSs (nt 27368-27413 of SEQ ID 1), a multicloning site containing restriction sites Spel, Notl, Sacll and Sall and a 373 nt genomic region (nt 28240-28622 of SEQ ID 1) comprising the TRS-N (5’TRS 20 nt, the core sequence and 3’TRS 8 nt) followed by the first 349 nt of gene N. The synthetic cDNA was cloned into PpuMI and Avril sites of plasmid pUC57-F6, containing the F6 fragment (SEQJD 14) with SARS-CoV-2 3’-end genome sequence (25,314-28,609 nt), leading to pUC57_F6_A678_TRS7-MCS_M-N, which was used as an intermediate plasmid for the subcloning of cDNAs including precursor sequences of miRNAs (pre-miRNA). cDNA fragments encoding miRNA precursors were chemically synthesized, including the characteristic stem-loop structure flanked at both 5’ and 3’ ends by 50 nt from the primary miRNA transcript, leading to pre-miRNA-155 (165 nt), pre-miRNA-181a (210 nt), pre- miRNA-223 (210 nt) and pre-miRNA-138 (199 nt). The subcloning of precursor miRNAs into Spel and Notl sites of pUC57_ F6_A678_TRS7-MCS_M-N led to a collection of plasmids encoding each individual pre-miRNA. These plasmids were digested with BamHI and Rsrll and the resulting fragments, which included the pre-miRNAs replacing 6, 7a, 7b and 8 accessory genes, were inserted into pBAC-SARS-CoV-2-FL that was previously digested with the same enzymes. As a result, pBAC-SARS-CoV-2_ A678_TRS7-miRNA_M-N plasmids including each precursor of human miRNAs between M and N genes were generated. Recombinant viruses were rescued in VeroTMPRSS2 cells from the pBAC-SARS-CoV- 2_ A678_TRS7-miRNA_M-N plasmids as described.
[0373] 11.2. Northern-blot of small RNAs
[0374] VeroTMPRSS2 and Calu-3 cells were infected at a MOI of 0.001 and 0.01 PFU, respectively, with the recombinant SARS-CoV-2-A[6,7,8] viruses encoding immunomodulatory miRNAs 155, 181a, 223 or 138. At 30 hpi in Vero-TMPRSS2 cells or 48 hpi in Calu-3 cells, intracellular RNA was collected and the small RNA fraction was purified using miRvana isolation kit (Thermo Fischer Scientific). 10 .g of small RNAs were mixed with 2x loading buffer containing formamide, heated for 3 minutes at 95°C and loaded into 15% denaturing urea-polyacrilamide gels. After 3 hours of electrophoresis at 80-120V, separated RNAs were transferred to a nitrocellulose membrane (Amersham Hybond NX, GE) using a Trans-Blot Turbo system (Bio-Rad). The transferred molecules were chemically crosslinked to the membranes by incubating with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) for 2 hours at 60 °C. Membranes were washed with DEPC-H2O and hybridized for 16 hours at 42 °C with 22 nucleotides 5’-biotin labeled DNA probes (5 pmol / mL) that are perfectly complementary to each mature miRNA sequence (Table 5). After hybridization, a Chemiluminiscent Nucleic Acid Detection Kit (Thermo Fischer Scientific) was used to detect small RNAs, according to the manufacturer’s recommendations. Briefly, membranes were blocked for 15 min with blocking buffer, incubated with stabilized Streptavidin-HRP conjugate diluted 1 :300 and equilibrated with a substrate equilibration buffer. Finally, miRNAs were detected using a chemiluminiscent substrate working solution based on luminol and peroxide solution mixed at 1 :1 ratio. Images of hybridized probes were captured using ChemiDoc (Bio-Rad). miRNA-93 and U6 small nucleolar RNA were used as endogenous miRNA and RNA loading controls, respectively.
[0375] Table 5. Sequences of DNA probes used for the specific detection of each miRNA by Northern Blot. The probes, 5’ end labeled with biotin, are complementary to the mature miRNA.
[0376] An expression cassette encoding candidate miRNA precursors (pre-miRNA) was inserted into the cDNA of SARS-CoV-2-A[6,7a,7b,8], at the site previously occupied by the accessory genes, following the transcription-regulating sequences (TRS) of gene 7a. TRS-7a was selected to drive the transcription of a viral subgenomic mRNA including the pre-miRNA sequence, since this TRS is one of the most potent TRSs during infection. Moreover, it was recently described that a viral miRNA-like small RNA was naturally expressed from ORF7a during SARS-CoV-2 infection in vivo and in cell cultures (Pawlika et al., 2021), which supports the potential of SARS-CoV-2 RNA genome to encode small non-coding RNAs (Fig. 30).
[0377] Immunomodulatory miRNAs-138, 181a, 155 and 223 were selected to be expressed by SARS-CoV-2 replicons. miRNA-223 is involved in the reduction of inflammageing by repressing the expression of inflammatory cytokines, while miRNAs-138, 181a, 155 participate in the enhancement of immune responses. In particular, miRNA-138 targets PDL1 and PD1 , thus promoting T cell responses, which are reduced in older adults.
[0378] Recombinant SARS-CoV-2-A[6,7a,7b,8] viruses encoding miRNA precursors of immunomodulatory miRNAs were rescued and amplified in VeroE6-TMPRRS2. Insertion of pre-miRNA sequences did not lead to significant changes in viral titers either in VeroE6-TMPRRS2 or in human lung Calu3 cells, as compared to the parental virus (Fig. 31). Genomic instability was not observed after three passages in cell cultures.
[0379] The expression of precursors of immunomodulatory miRNAs from the viral genome and their processing to mature miRNAs (22nt) in Calu3 (Fig. 32) and VeroE6-TMPRRS2 (Fig. 33) cells was confirmed by Northern-blot using specific probes. MiRNA precursors, 60-100 nt in length, of each candidate miRNA were specifically detected in cells infected with the engineered recombinant viruses, while were absent in cells infected with the parental viruses SARS-CoV-2-WT and SARS-CoV-2-A[6,7,8], Processing of pre- miRNAs to the mature miRNA, 22 nt in length, was confirmed in both cell lines. Different amounts of each candidate pre-miRNA and its mature miRNA were observed in a same cell line, suggesting that sequence differences may contribute to the regulation of miRNA expression levels.
[0380] These results provide the proof of concept for the delivery of cellular miRNAs by SARS- CoV-2 recombinant viruses with the purpose of modulating the host immune response.
[0381] SEQUENCE LISTING
[0382] SEQ ID NO: 1 : SARS-CoV-2 without amendments Genbank: MN908947.3 47
[0383] SEQ ID NO: 2: VO; SARS-CoV-2-A[3, E,6,7,8]
[0384] SEQ ID NO: 3: V1; SARS-CoV-2- nsp1AD-A[,3,E,6,7,8]
[0385] SEQ ID NO: 4: S gene polynucleotide sequence without amendments
[0386] SEQ ID NO: 5: SARS-CoV-2 S gene polynucleotide sequence codon-optimized for human codon usage
[0387] SEQ ID NO: 6: protein 3a amino acid sequence GenBank YP_009724391
[0388] SEQ ID NO: 7: protein E amino acid sequence GenBank YP_009724392
[0389] SEQ ID NO: 8: pBAC-SARS-CoV-2-FL: pBAC sequence (nucleotides 1 to 7889), SARS- CoV-2 genome sequence (nucleotides 7890 to 37784) and pBAC sequence (nucleotides 37785 to 38125), including genetic markers in the form of silent mutations SEQ ID NO: 9: F1 fragment SARS-CoV-2 polynucleotide sequence
[0390] SEQ ID NO: 10: F2 fragment SARS-CoV-2 polynucleotide sequence SEQ ID NO: 11 : F3 fragment SARS-CoV-2 polynucleotide sequence SEQ ID NO: 12: F4 fragment SARS-CoV-2 polynucleotide sequence SEQ ID NO: 13: F5 fragment SARS-CoV-2 polynucleotide sequence SEQ ID NO: 14: F6 fragment SARS-CoV-2 polynucleotide sequence SEQ ID NO: 15: SARSCoV2-A3 polynucleotide sequence SEQ ID NO: 16: SARSCoV2-AE polynucleotide sequence SEQ ID NO: 17: SARSCoV2-A[3,E] polynucleotide sequence
[0391] SEQ ID NO: 18: SARS-CoV-2-A6 polynucleotide sequence, containing two point substitutions (c.27041A>0 and c.27044A>0) in comparison to SEQ ID NO: 1.
[0392] SEQ ID NO: 19: SARS-CoV-2-A7 polynucleotide sequence, wherein 7a and 7b genes were deleted. SEQ ID NO: 20: SARS-CoV-2-A7a polynucleotide sequence
[0393] SEQ ID NO: 21 : SARS-CoV-2-A7b polynucleotide sequence
[0394] SEQ ID NO: 22: SARS-CoV-2-A8 polynucleotide sequence
[0395] SEQ ID NO: 23: SARS-CoV-2-A[6,8] polynucleotide sequence, containing two point substitutions (c.27041A>C and c.27044A>C) in comparison to SEQ ID NO: 1
[0396] SEQ ID NO: 24: SARS-CoV-2-A[6,7,8] polynucleotide sequence, containing two point substitutions (C.27041A0C and C.27044A0C) in comparison to SEQ ID NO: 1
[0397] SEQ ID NO: 25: Fnsp1-AD polynucleotide sequence: pUC57 sequence (nucleotides 1 to 42) and SARS-CoV-2 nsp1-AD sequence (nucleotides 43-836)
[0398] SEQ ID NO: 26: WH-25155-VS
[0399] SEQ ID NO: 27: WH-28957-RS
[0400] SEQ ID NO: 28: SARS-CoV-2 genomic RNA forward primer
[0401] SEQ ID NO: 29: SARS-CoV-2 genomic RNA reverse primer
[0402] SEQ ID NO: 30: MGB probe 1
[0403] SEQ ID NO: 31 : subgenomic messenger RNA (sgmRNA) N forward primer
[0404] SEQ ID NO: 32: subgenomic messenger RNA (sgmRNA) N reverse primer
[0405] SEQ ID NO: 33: MGB probe 2
[0406] SEQ ID NO: 34: SARS-CoV-2 S protein amino acid sequence, encoded by SEQ ID
[0407] NO: 4
[0408] SEQ ID NO: 35: SARS-CoV-2 S protein amino acid sequence, encoded by SEQ ID
[0409] NO: 5
[0410] SEQ ID NO: 36: SARS-CoV-2 ORF8 gene sequence
[0411] SEQ ID NO: 37: SARS-CoV-2 ORF6 gene sequence
[0412] SEQ ID NO: 38: SARS-CoV-2 ORF7a gene sequence
[0413] SEQ ID NO: 39: SARS-CoV-2 ORF7b gene sequence
[0414] SEQ ID NO: 40: F4 fragment SARS-CoV-2 polynucleotide sequence of Delta variant
[0415] SEQ ID NO: 41: F4 fragment SARS-CoV-2 polynucleotide sequence of Omicron variant
[0416] SEQ ID NO: 42: SARS-CoV-2-A[3,E,6,7] polynucleotide sequence
[0417] SEQ ID NO: 43: SARS-CoV-2-A[3,E,7,8] polynucleotide sequence
[0418] SEQ ID NO: 44: SARS-CoV-2-A[3,E,6,8] polynucleotide sequence
[0419] SEQ ID NO: 45: Fnsp1_AA polynucleotide sequence
[0420] SEQ ID NO: 46: Fnsp1_A[B,D] polynucleotide sequence
[0421] SEQ ID NO: 47: SARS-CoV-2-A[3,E,6] polynucleotide sequence, containing two point substitutions (c.27041A>C and c.27044A>C) in comparison to SEQ ID NO: 1
[0422] SEQ ID NO: 48: SARS-CoV-2-A[3,E,7] polynucleotide sequence
[0423] SEQ ID NO: 49: SARS-CoV-2-A[3,E,8] polynucleotide sequence SEQ ID NO: 50: SARS-CoV-2-A[3,E,6,8] polynucleotide sequence, containing two point substitutions (c.27041A>C and c.27044A>C) in comparison to SEQ ID NO: 1 SEQ ID NO: 51 : SARS-CoV-2-A[3,E,6,8], D614G, AFCS mutant polynucleotide;
[0424] SEQ ID NO: 52: SARS-CoV-2-A[3,E,6,8], D614G and KR mutant polynucleotide;
[0425] SEQ ID NO: 53: SARS-CoV-2-A[3,E,6,8] D614G, AFCS and KR mutant polynucleotide
[0426] SEQ ID NO: 54: miRNA138 polynucleotide sequence
[0427] SEQ ID NO: 55: miRNA155 polynucleotide sequence
[0428] SEQ ID NO: 56: miRNA181a polynucleotide sequence
[0429] SEQ ID NO: 57: miRNA223 polynucleotide sequence
[0430] SEQ ID NO: 58: codon-optimized SARS-CoV-2 ORF3a polynucleotide sequence
[0431] SEQ ID NO: 59: codon-optimizedSARS-CoV-2 ORF E polynucleotide sequence
[0432] REFERENCES
[0433] Almazan, et al., 2000. Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5516- 21. doi: 10.1073 / pnas.97.10.5516.
[0434] Almazan et al., 2013. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio. 2013 Sep 10;4(5):e00650-13. doi: 10.1128 / mBio.00650-13. PMID: 24023385; PMCID: PMC3774192.
[0435] Almazan et al. , 2014. Coronavirus reverse genetic systems: Infectious clones and replicons. Virus Res. 2014 Aug 30:189:262-70. doi: 10.1016 / j.virusres.2014.05.026. Epub 2014 Jun 12.
[0436] Almazan et al., 2015. Engineering infectious cDNAs of coronavirus as bacterial artificial chromosomes. Methods Mol Biol. 2015 1282:135-52. doi: 10.1007 / 978-1- 4939-2438-7_13. PMID: 25720478; PMCID: PMC4726977.
[0437] Dediego et al. , 2028. Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. Virology. 2008 Jul 5;376(2):379-89. doi: 10.1016 / j.virol.2008.03.005. Epub 2008 May 2. PMID: 18452964; PMCID: PMC2810402. Gutierrez-Alvarez et al, 2021., Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice. Proc Natl Acad Sci USA. 2021 Oct 26;118(43):e2111075118. doi: 10.1073 / pnas.2111075118.
[0438] Jimenez-Guardeno et al., 2014. The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. PLoS pathogens. 10(8), e1004320.
[0439] Johnson et al., 2021., Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021 Mar;591(7849):293-299. doi: 10.1038 / s41586-021-03237- 4. Epub 2021 Jan 25
[0440] Kumar et al., 2018. Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc. 2018 Jun 1;2018(6). doi: 10.1101 / pdb.prot095505.
[0441] Mairhofer et al., 2008. A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy. Biotechnol J. 2008 Jan;3(1):83-9. doi: 10.1002 / biot.200700141. PMID: 17806101.
[0442] Mairhofer and Grabherr, 2008. Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA. Mol Biotechnol. 2008 Jun;39(2):97-104. doi: 10.1007 / s12033-008-9046-7. PMID: 18327557.
[0443] Nieto-Torres et al., 2014. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014 May 1 ;10(5):e1004077. doi: 10.1371 / journal.ppat.1004077. eCollection 2014 May
[0444] Pawlika et al., 2021. SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. Proc Natl Acad Sci U S A. 2021 Dec 28;118(52):e2116668118. doi: 10.1073 / pnas.2116668118. Epub 2021 Dec 13.
[0445] Silvas et al., 2021. Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice. J Virol. 2021 Aug 10;95(17):e0040221. doi: 10.1128 / JVI.00402-21. Epub 2021 Aug 10. PMID: 34133899; PMCID: PMC8354228. Wang et al., 2023. Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB. Cell Discov. 2023 Jul 28;9(1):80. doi: 10.1038 / S41421 -023-00575-7.
[0446] Wang et al., 2023. Cell type dependent stability and virulence of a recombinant SARS-CoV-2, and engineering of a propagation deficient RNA replicon to analyze virus RNA synthesis. Front Cell Infect Microbiol. 2023 Oct 24:13:1268227. doi: 10.3389 / fcimb.2023.1268227. eCollection 2023.
[0447] Wu et al., 2021. Nucleocapsid mutations R203K / G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host and Microbe, 29(12), 1788-1801. e6. https: / / doi.Org / 10.1016 / j.chom.2021 .11.005 Zhang et al., 2021. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. Cell. 2021 Apr 15;184(8):2229- 2238. e13. doi: 10.1016 / j.cell.2021.02.044. Epub 2021 Feb 23. PMID: 33691138; PMCID: PMC7901297.
Claims
CLAIMS1. A polynucleotide comprising:(a) a polynucleotide sequence of SEQ ID NO: 42 (SARS-CoV-2A[3, E, 6 and 7] mutant) or SEQ ID NO: 43 (SARS-CoV-2A[3, E, 7 and 8] mutant); or(b) a variant of SEQ ID NO: 42 or a variant of SEQ ID NO: 43, wherein the variant has at least 96 % identity, preferably at least 97 % or at least 98 % or at least 99 % identity to SEQ ID NO: 42 or SEQ ID NO: 43.
2. The polynucleotide according to claim 1, wherein the variant polynucleotide sequence is further characterized in that:(b1) the variant encodes a replication-competent mutant of the SARS-CoV-2 RNA genome, wherein replication-competent means that the mutant SARS-CoV-2 RNA genome can produce copies upon transfection of VeroE6-TMPRSS2 cells; and(b2) the variant encodes a propagation-defective mutant of the SARS-CoV-2 RNA genome, wherein propagation-defective means that upon transfection of VeroE6-TMPRSS2 cells the mutant SARS-CoV-2 RNA genome is not able to assemble a virus or a VLP on the basis of the proteins encoded in the variant polynucleotide, which virus or VLP would be capable of infecting other VeroE6-TMPRSS2 cells.
3. The polynucleotide according to claim 1 or 2, wherein the variant polynucleotide sequence is further characterized in that:(c) upon infection or transfection of a VeroE6-TMPRSS2 cell culture the mutant SARS-CoV-2 RNA genome is able to produce a viral titre of at least 103FFU / ml or a viral titre of at least 104FFU / ml or at least 105FFU / ml or at least 106FFU / ml.
4. The polynucleotide according to one of claims 1 to 3, wherein the variant polynucleotide:(d1) does not comprise a sequence encoding a protein corresponding to the proteins of ORF 3a, ORF E, ORF 6 and ORF 7; or(d2) does not comprise a sequence encoding a protein corresponding to the proteins of ORF 3a, ORF E, ORF 7 and ORF 8.
5. The polynucleotide according to one of claims 1 to 4, wherein SEQ ID NO: 43, SEQ ID NO: 42 or the respective the variant polynucleotide:(e) comprises a deletion of at least 18 consecutive nucleotides in the sequence encoding a full-length nsp1 domain consisting of nucleotides 266 to 805 of SEQ ID NO: 43 or SEQ ID NO: 42; and / or(f) comprises a deletion of at least 6 consecutive nucleotides in the sequence encoding a furin cleavage site consisting of nucleotides 23603 to 23617 of SEQ ID NO: 43 or SEQ ID NO: 42.
6. A polynucleotide comprising:(a) a variant of SEQ ID NO: 42, wherein the variant contains the D614G mutation (SARS-CoV-2A[3, E, 6 and 7]);(b) the sequence of SEQ ID NO: 51 (SARS-CoV-2A[3, E, 6 and 7] mutant further comprising the D614G and AFCS mutation);(c) the sequence of SEQ ID NO: 52 (SARS-CoV-2A[3, E, 6 and 7] mutant further comprising the D614G and KR mutation);(d) the sequence of SEQ ID NO: 53 (SARS-CoV-2A[3, E, 6 and 7] mutant further comprising the D614G, AFCS and KR mutations); or(e) a variant of one of alternatives (b) to (d), wherein the variant has a sequence identity of at least 99% to one of the sequences of SEQ ID NO: 51 , 52 or 53.
7. The polynucleotide according to one of claims 1 to 6, further comprising an miRNA sequence.
8. The polynucleotide according to claim 7, wherein the miRNA sequence comprises:(a) the sequence of SEQ ID NO: 54 (miRNA138);(b) the sequence of SEQ ID NO: 55 (miRNA155);(c) the sequence of SEQ ID NO: 56 (miRNAI 181a);(d) the sequence of SEQ ID NO: 57 (miRNA223); or(e) a variant miRNA sequence of one of alternatives (a) to (d), wherein the variant has a sequence identity of at least 99% to one of the sequences of SEQ ID NO: 54, 55, 56 or 57.
9. A polynucleotide comprising the sequence of SEQ ID NO: 53 (SARS-CoV-2A[3, E, 6 and 7] mutant comprising the D614G, AFCS and KR mutations), which inaddition to the sequence of SEQ ID NO: 53 contains one of the miRNA sequences of SEQ ID NO: 54 (miRNA138), SEQ ID NO: 55 (miRNA155), SEQ ID NO: 56 (miRNA181a) and SEQ ID NO: 57 (miRNA223).
10. The polynucleotide according to one of claims 1 to 9, wherein the polynucleotide is RNA or DNA.
11. A Virus Like Particle (VLP) comprising a polynucleotide according to one of claims 1 to 10.
12. An expression vector comprising a DNA sequence comprising a polynucleotide of one of claims 1 to 10.
13. A cell transfected with polynucleotide according to one of claims 1 to 10, infected with the VLP according to claim 11 and / or transfected with the expression vector according to claim 12, wherein the cell further contains a recombinant sequence encoding ORF 3a and ORF E of SARS-CoV-2.
14. A cell according to claim 12 or 13, wherein the host cell contains:• a sequence encoding ORF 3a comprising SEQ ID NO: 6 (3a gene) or a sequence comprising SEQ ID NO: 58 (codon-optimized 3a gene); and• a sequence encoding ORF E comprising SEQ ID NO: 7 (E gene) or a sequence comprising SEQ ID NO: 59 (codon-optimized E gene).
15. A cell according to one of claims 12 to 14, wherein sequence encoding ORF 3a of SARS-CoV-2 is expressed under the control of a CMV promoter and the sequence encoding ORF E of SARS-CoV-2 is expressed under the control of a CMV promoter.
16. A cell according to one of claims12 to 15, wherein the cell is selected from cell lines VeroE6-TMPRSS2, Vero E6 or BHK21.
17. A method of producing a VLP comprising the steps of:(a) transfecting a cell with an expression vector according to claim 11 , wherein the cell expresses a protein encoded by the ORF3a gene comprising SEQ ID NO: 6 or SEQ ID NO: 58 (codon-optimized 3a gene)and a polypeptide encoded by ORF E gene comprising SEQ ID NO: 7 or SEQ ID NO: 59 (codon-optimized E gene); and(b) purifying the VLPs from the supernatant.
18. A vaccine composition comprising a VLP according to claim 10 or a polynucleotide according to one of claims 1 to 9, and optionally further comprising:- at least one pharmaceutically acceptable excipient and / or- at least one chemical or biological adjuvant or immunostimulant.
19. A vaccine composition comprising:(a) a VLP which comprises a polynucleotide comprising the sequence of SEQ ID NO: 53 (SARS-CoV-2A[3, E, 6 and 7] mutant comprising the D614G, AFCS and KR mutations), which in addition to the sequence of SEQ ID NO: 53 contains one of the miRNA sequences of SEQ ID NO: 54 (miRNA138), SEQ ID NO: 55 (miRNA155), SEQ ID NO: 56 (miRNA181a) and SEQ ID NO: 57 (miRNA223);(b) optionally further comprising:- at least one pharmaceutically acceptable excipient and / or- at least one chemical or biological adjuvant or immunostimulant.
20. The vaccine composition according to claim 18 or 19, for use in protecting a patient against SARS-CoV-2 infection.
21. The vaccine composition according to one of claims 18 to 20, wherein the composition is formulated for topical, intranasal, oral, subcutaneous or intramuscular administration, wherein the vaccine is preferably administered using a dosage regimen comprising a first administration at day 1 and at least one further administration at least 21 days later.
22. The vaccine composition according to one of claims 18 to 21 , wherein the vaccine comprises two different polynucleotides according to one of claims 1 to 9, wherein:(a) one polynucleotide comprises the gene coding for protein S of the Delta strain comprising nucleotides 1479 to 5228 of SEQJD 40 or variant thereof having at least 96 % identity, preferably at least 97 % or at least98 % or at least 99 % identity to nucleotides 1479 to 5228 of SEQ ID NO: 40; and(b) the other polynucleotide comprises the gene coding for protein S of the Omicron strain comprising nucleotides 1479 to 5216 of SEQJD 41 or variant thereof having at least 96 % identity, preferably at least 97 % or at least 98 % or at least 99 % identity to nucleotides 1479 to 5216 of SEQ ID NO: 41.
Citation Information
Patent Citations
Coronaviruses, vaccines comprising the same, and methods for preventing disease
WO2018160977A1
Coronavirus derived RNA replicons and their use as vaccines
WO2023094595A1
Coronavirus RNA replicons and use thereof as vaccines
US20230203536A1
Coronavirus RNA replicons and use thereof as vaccines
WO2021240039A1
A trans- complementation system for SARS-COV-2
WO2022155521A1
